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2SUMMARY
In vitro evidence suggests that interleukin-6 (IL-6) is a major mediator of the acute 
phase response. The aims of this work were threefold: firstly, to validate a bioassay 
for the measurement of IL-6 in serum; secondly, to characterise the role of IL-6 in 
the acute phase response and determine its potential as a marker of tissue damage 
using elective surgical patients as models of controlled trauma; and thirdly, to 
assess its value in four clinical situations : post-operative complications; suspected 
myocardial infarction; pancreatitis; and rheumatoid arthritis.
The validation of a hybridoma growth stimulation assay using the mouse 7TD1 cell 
line with colorimetric evaluation of cell numbers is described. This assay was used 
to measure serum IL-6 concentrations at timed intervals post-operation in 39 
patients from 6 broad surgical categories. Serum IL-6 rose within 2 to 4 hours of 
incision in all surgical groups. The magnitude of the IL-6 response was strongly 
associated with duration of surgery, and was associated significantly with C- 
reactive protein (CRP) response, increase in axillary temperature and reduction in 
zinc/albumin ratio.
Surgical patients who subsequently developed complications had higher IL-6 
concentrations 24 hours post-operation than those who did not.
Serum IL-6 was also measured in 15 patients with suspected myocardial infarction, 
in 23 patients with acute pancreatitis, and in 33 patients with rheumatoid arthritis. 
In patients with suspected myocardial infarction, admission serum IL-6 
concentration discriminated completely between those with angina and those who 
had suffered myocardial infarction, and was strongly associated with left 
ventricular ejection fraction on the third hospital day. Patients who had severe 
pancreatitis had higher serum IL-6 levels on admission than those with mild
disease. Serum IL-6 concentrations in rheumatoid arthritis were significantly 
associated with clinical disease activity.
These results are consistent with the hypothesis that IL-6 is a major mediator of the 
systemic inflammatory response, and indicate that it behaves as an early, 
quantitative marker of tissue damage. Its measurement is likely to be of value in 
clinical practice, particularly in acute situations, but larger numbers of patients 
require to be studied to confirm these findings.
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INTRODUCTION
Interleukin-6 (IL-6) is one of the more recently described members of the 
interleukin family. The interleukins are cytokines (i.e. cellular messenger proteins) 
which are involved in the modulation of host defence mechanisms such as 
inflammation, the immune response and the metabolic response to injury. IL-6 has 
been found to have a wide spectrum of biological activities, and this diversity 
created considerable confusion over nomenclature (which was based mainly on 
functional properties) in the 1980s.
Historical Review of IL-6
Several groups involved in the identification of apparently unrelated cytokines 
eventually concluded that these cytokines were all one and the same protein 
molecule. As a result this protein factor was known by a number of different 
names based on identified characteristics.
Three main strands of investigation occurring in parallel were involved:
1. INTERFERON BETA-2 / 26 KILODALTON PROTEIN
IL-6 was discovered in 1980 as a product co-induced in human fibroblasts which 
had been stimulated for interferon-beta (IFNp) expression (1). Weissenbach et al 
isolated two messenger RNA species, one coding for interferon-beta and the second 
coding for a protein with a molecular weight of 23 to 26 kilodaltons. This protein 
was named interferon beta-2 (IFNp2) and was described independently by other 
investigators (2). However, Content et al named the protein “26 K factor” or “26 
kD protein” because they concluded that it had no antiviral activity (3). The same 
workers also reported that its transcription was regulated differently from that of 
interferon beta (4), and that this protein was induced by a factor belonging to the 
interleukin-1 family (5), suggesting that it played a role as an intermediary or
23
effector molecule in inflammatory or immunoregulatory processes. Subsequent 
sequencing of the protein in 1986 confirmed the lack of structural homology with 
interferon beta (6). However, the physiological function of interferon beta-2/26 
kilodalton protein remained obscure.
2. B CELL DIFFERENTIATION FACTOR /  B CELL STIMULATING 
FACTOR-2
Meantime, Yoshizaki et al had isolated and purified a B cell differentiation factor 
(initially called BCDF) from a human B cell line (7). This factor was shown to 
induce the final maturation of B cells into immunoglobulin-secreting cells (8) and 
was renamed B cell stimulating factor-2 (BSF-2). It was cloned from a leukaemia 
virus transformed human T cell line and the primary sequence of B cell stimulating 
factor-2 was deduced from the complementary DNA (9). By 1987 it was apparent 
that B cell stimulating factor-2 was identical to interferon beta-2 (10).
3. INTERLEUKIN HYBRIDOMA PLASMACYTOMA-1 / 
PLASMACYTOMA GROWTH FACTOR / HYBRIDOMA / 
PLASMACYTOMA GROWTH FACTOR
The third line of research involved the study of growth factors for plasmacytomas 
and B cell hybridomas. In 1986, a hybridoma growth factor was purified from the 
supernatant of a murine helper T cell line (interleukin hybridoma plasmacytoma-1 
(IL-HP1)) (11) and from murine macrophage supernatant (plasmacytoma growth 
factor (PCT-GF)) (12). This led Van Damme et al to purify a human 
hybridoma/plasmacytoma growth factor (HPGF) produced by an osteosarcoma cell 
line treated with interleukin-1 (13). Surprisingly, the amino terminal of this factor 
was unlike that of the murine factor but identical to that of the interferon beta-2 / 
B cell stimulating factor-2 molecule (14). This identity was confirmed by 
independent cloning and sequence analysis (15), and by demonstrating that
24
recombinant 26 kilodalton protein had hybridoma plasmacytoma growth factor 
activity (16).
The realisation that these apparently unrelated cytokines were one and the same 
molecule led to the proposal that it be designated ‘interleukin-6’ to avoid further 
confusion over nomenclature (16,17). Thus the molecule first isolated in 1980 was 
finally named interleukin-6 in 1987.
By 1988, three further biological actions had been attributed to IL-6:
1. In 1983 Ritchie and Fuller had described a monocyte-derived polypeptide 
involved in the regulation of hepatic acute phase protein synthesis, which they 
had called hepatocyte stimulating factor (HSF) (18). This factor seemed to be 
responsible for controlling the full hepatic acute phase protein response whereas 
interleukin-1 (IL-1) and tumour necrosis factor alpha (TNFa), cytokines 
previously thought to have been the principal inducers of this response, had 
been shown to produce only a restricted acute phase response in vitro (19). In 
1987, Gauldie et al reported that hepatocyte stimulating factor was 
immunologically and functionally identical to IL-6 (20). In other words, IL-6 
was a hormone which interacted with liver cells to induce the synthesis of a 
spectrum of plasma proteins characteristic of the hepatic acute phase reaction.
2. Other workers demonstrated that IL-6 was able to stimulate haematopoiesis 
(21 ,22).
3. IL-6 was shown to be active in the differentiation of cytotoxic T lymphocytes 
(cytotoxic T cell differentiation factor (CDF)) (23).
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The nomenclature relating to IL-6 is summarised below:
IFN|32
26 K
BCDF
BSF-2
IL-HP1
PCT -GF
HPGF
HSF
CDF
= INTERLEUKIN-6
IL-6 Gene and Protein Structure
The human IL-6 gene has been localised to chromosome 7 p 21 (24,25), and 
consists of five exons and four introns. Its organisation is strikingly similar to that 
of the granulocyte-colony stimulating factor gene (26) suggesting that these genes 
are evolutionarily derived from a common ancestor gene.
The complementary DNA for human IL-6 predicts that the protein consists of 184 
amino acids with two potential N-glycation sites and four cysteine residues (9). It 
is formed by the cleavage of a 28 amino acid signal peptide from a 212 amino acid 
precursor protein with a molecular mass of 26 kilodaltons (thus the synonym 26 
kilodalton protein) (9), and then N and O glycated before secretion (27). IL-6 thus 
exists in at least 5 different forms (molecular weight ranging from 21-28 kd) 
resulting from different glycations (28). These differences in post-translational 
modification may explain how such a multipotent cytokine can produce tissue 
specific effects, and may cause differences in its plasma half-life.
26
Regulation of IL-6 Production
IL-6 has been shown to be produced by an apparendy endless variety of cells 
including monocytes (29), macrophages (30), lymphocytes (11), endothelial cells 
(31), fibroblasts (13), keratinocytes (32), mast cells (33), astrocytes (34), anterior 
pituitary cells (35) and numerous tumour cell lines (36-41). Usually these cells do 
not produce IL-6 constitutively but require appropriate stimulation, e.g. viral 
infection, lipopolysaccharide (LPS) or cytokine administration (table 1). Different 
cell lines require different stimulants for optimal IL-6 production. For example, 
monocytes/macrophages are preferentially stimulated by lipopolysaccharide 
whereas fibroblasts respond better to the cytokines IL-1 and TNFa, suggesting that 
these cytokines are key factors in IL-6 production. Lipopolysaccharide, TN Fa and 
IL-1 are all potent inducers of IL-6 production by endothelial cells (table 1). It has 
been shown that glucocorticoids negatively regulate IL-6 gene expression in 
various cells (50). In spite of the large variety of cells known to secrete IL-6, it is 
probable that endothelial cells, Fibroblasts and monocytes/macrophages are the 
principal producers of IL-6 during inflammation. These cells have a high capacity 
for IL-6 production and are distributed widely throughout the body.
The kinetics of IL-6 messenger RNA expression vary among the different cell 
types. Maximal messenger RNA expression occurs 3 hours after stimulation of 
monocytes (28) but over 24 hours after stimulation of T cells (51). These 
differences in kinetics probably reflect differing functions of the IL-6 molecule at 
different stages during the immune / inflammatory response. Both diacylglycerols, 
which activate the protein kinase pathway (52), and agents which increase 
intracellular cyclic AMP (53) enhance the accumulation of IL-6 messenger RNA. 
Thus it appears that at least two mechanisms exist for IL-6 gene expression.
In addition to much in vitro work, many in vivo studies have been performed to 
study the factors involved in IL-6 production. The first of these was the
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Cells Stimulants Effect
Monocytes/Macrophages LPS +++ (18, 28, 30)
HIV +++ (42)
IL-1 ++ (28)
TNFa - (28)
Fibroblasts IL-1 +++ (13, 16)
- Viruses +++ (43,44)
E coli +++ (44)
TNF a ++ (13,45,46)
LPS + (44)
Endothelial Cells IL-1 +++ (47, 48)
TNF a +++ (47, 48)
LPS +++ (47, 48)
Keratinocytes IL-1 + (41)
Sinoviocytes IL-1 +++ (49)
TNFa ++ (49)
Key: +++ = very strong stimulation of IL-6 production; ++ = strong stimulation;
+ = weak stimulation; -  = no stimulation
Table 1: Regulation of IL-6 production in vitro.
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demonstration by Coulie et al that injection of lipopolysaccharide into mice 
produced detectable IL-6 levels in plasma (30). High plasma IL-6 concentrations 
have been reported in rats subjected to psychological stress (54), and adrenalin 
administration to rats has been found to evoke high plasma concentrations of IL-6 
(55). This effect was blocked by propanolol. Injection of recombinant IL-1 
(56,57) and TN Fa (57) into mice caused production of substantial amounts of IL-6 
within 30 mins, while administration of endotoxin (E coli derived 
lipopolysaccharide) (57) and zymosan (58) resulted in peak circulating IL-6 levels 
occurring approximately 2 hours post-administration. The effects of endotoxin 
appear to be mediated at least in part by TNFa, since injection of anti-TNFa 
antibody caused a reduction in the EL-6 response to endotoxin (57). Further support 
for the premise that TNFa is crucial in the initiation or amplification of IL-6 release 
was provided by the finding that passive immunisation of baboons against TNFa 
prior to the administration of lethal doses of E coli resulted in an attenuated plasma 
IL-6 response (59).
Recent in vivo work in humans supports the hypothesis that IL-1 and TNFa are 
important stimulators of IL-6 production. These reports are discussed later in this 
chapter in the section ‘Clinical Studies of IL-6’ (page 39).
Matsuda et al reported that alpha-2 macroglobulin acts as a carrier protein for IL-6 
in plasma (60). IL-6 bound to alpha-2 macroglobulin retains its biological activity 
and becomes resistant to proteases, whereas free IL-6 is easily degraded. By 
binding to alpha-2 macroglobulin, locally produced IL-6 is made available 
systemically.
Receptor and Signal Transduction
IL-6 receptor complementary DNA was found to encode a typical membrane 
protein consisting of 468 amino acids including a signal peptide of approximately 
19 amino acids (61). The extracellular portion of the molecule contains
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approximately 340 amino acids with a 90 residue domain resembling that of the 
immunoglobulin family. The transmembrane portion of the molecule consists of 
approximately 28 residues and is followed by a cytoplasmic segment containing 
approximately 82 amino acids. This last portion of the molecule appears to play no 
role in the transduction of the IL-6 signal (62), for which the mechanisms as yet 
remain unclear. However, it appears that cell-type specific responses to IL-6 are 
not due to cell-type specific forms of the receptor but to other unknown elements of 
the signal transduction cascade. Taga et al described how binding of IL-6 to its 
receptor triggered the association of the receptor with a non-ligand binding 
membrane glycoprotein (62). Fey et al have identified an TL-6-response-element’ 
in the rat alpha-2 macroglobulin gene (a prototype rat liver acute phase gene) which 
serves as a binding site for nuclear factors, as yet uncharacterised, that facilitate 
hormone induced transcription (63).
IL-6 receptors have been found in hepatocytes, fibroblasts, epithelial cells, 
haematopoietic lines and cells of neural origin (64-66). Particularly high numbers 
have been found on human multiple myeloma cells (64). Two classes of binding 
sites have been described: high affinity sites with a dissociation constant of 
approximately 10 picomolar; and low affinity sites with a dissociation constant of 
approximately 1 nanomolar (61).
Biological Functions of IL-6
It will be apparent that IL-6 is a multipotent cytokine, and most of its functions will 
be considered here only briefly. Its role in the acute phase response is of particular 
relevance to this thesis and will be considered in more detail at the end of this 
section.
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IMMUNE SYSTEM 
B Cell
As mentioned previously, IL-6 used to be called B cell stimulatory factor 2 because 
it was found to induce the final maturation of B cells into antibody producing cells 
(8) and so stimulate immunoglobulin production in vitro (9,67). IL-6 also 
stimulated m  vivo antibody production in mice (68). These and other studies 
demonstrate that IL-6 is an essential factor for B cell differentiation and antibody 
production, and may act synergistically with IL-1 (69). IL-6 is thought not to be 
involved in the proliferation of activated B cells (67). The effect of IL-6 on 
tumours of B cell origin is discussed in the sub-section ‘Hybridoma/Plasmacytoma 
Cells’ (page 31).
T Cell
Resting T cells express IL-6 receptors in contrast to resting B cells which do not 
(only activated B cells express IL-6 receptors) (64). This supports the premise that 
while IL-6 acts only on the final maturation stage of activated B cells, it is effective 
on resting T cells. IL-6 was found to promote the growth of phytohaemagglutinin 
stimulated thymocytes and peripheral T cells (70-72), an effect only partly inhibited 
by anti-interleukin-2 antibody which suggests that IL-6 may regulate T cell 
function independent of interleukin-2 to some degree (73). Moreover, the 
thymocyte co-stimulatory activity of macrophage derived conditioned medium was 
largely abrogated by anti-IL-6 antibody (74) (previously, IL-1 was thought to exert 
this activity). IL-6 stimulates interleukin-2 production by murine T cells (75) and 
enhances the interleukin-2 responsiveness of mitogen stimulated T cells and 
thymocytes (76). Since interleukin-2 is pivotal in T cell activation and 
proliferation (77), these results strongly support the premise that IL-6 is an 
essential accessory signal which promotes T cell activation and proliferation. It 
may act in synergy with IL-1 (76) and possibly TNFa (78). IL-6 has been found to
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induce not only T cell proliferation but also differentiation of cytotoxic T cells 
from human thymocytes and splenic T cells in the presence of interleukin-2 
(23,79).
MESANGIAL CELLS
Recent in vitro work suggests that IL-6 is an autocrine growth factor for mesangial 
cells. These cells express IL-6 messenger RNA and secrete IL-6 which has growth 
factor activity (80).
HAEMATOPOIESIS
The positive effect of IL-6 on haematopoiesis was first described by Ikebuchi et al 
who found that interleukin-3 and IL-6 acted synergistically to support the formation 
of multilineage blast cell colonies in murine spleen cell cultures (21). IL-6 appears 
to act on multipotent progenitors but not on more mature progenitors (81). The 
haematopoietic activity of IL-6 may prove valuable in the field of bone marrow 
transplantation. Prior incubation of murine bone marrow cells with IL-6 
dramatically increased the survival rate when the marrow cells were transplanted to 
lethally irradiated mice (82). Moreover, perfusion of IL-6 in 5-fluorouracil treated 
mice was found to accelerate the recovery in the numbers of haematopoietic stem 
cells (83). Other in vivo studies in mice (84) and monkeys (85) have shown that 
injection of human recombinant IL-6 results in dose dependent increases in platelet 
count. This effect on thrombopoeisis is partly explained by the finding that the N 
terminal sequence of thrombopoetin is identical to that of human IL-6 (86).
HYBRIDOMA/PLASMACYTOMA CELLS
The growth stimulation of these cells by IL-6 has been discussed on page 23 in the 
section ‘Historical Review of IL-6’. IL-6 has been implicated in the pathogenesis 
of multiple myeloma and plasma cell dyscrasias. Multiple myeloma cells have 
been shown both to produce and contain IL-6 (87,88), and to express the IL-6
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receptor (64,87) -  findings which support the existence of an autocrine positive 
feedback loop. IL-6 appears to act as a growth factor for myeloma cells (89,90), 
and in vitro myeloma cell responsiveness to IL-6 is directly related to disease 
severity (89). Moreover, Brandt et al demonstrated that transplantation of the 
coding sequences of the IL-6 gene into the haematopoietic cells of mice produced 
a syndrom e (C astlem an’s D isease) charac terised  by anaem ia, 
hypergammaglobulinaemia, splenomegaly and lymphadenopathy associated with 
extensive plasma cell infiltration of spleen, lung, liver and lymph nodes (91).
NEUROENDOCRINE
Stimulation of astrocytoma cells results in expression of IL-6 messenger RNA 
(34), suggesting that IL-6 may affect nerve cell growth or function. Indeed EL-6 
has been shown to induce the differentiation of chromaffin cells into neural cells 
and to maintain the viability of these cells (92). In vitro work has shown that 
hypothalamic (93) and pituitary cells (94) can produce IL-6, and in vivo work has 
demonstrated that IL-6 may be involved in the regulation of the hypothalamic- 
pituitary-adrenal axis. Intravenous administration of IL-6 to rats results in dose- 
dependent increases in plasma adrenocorticotrophic hormone (ACTH) levels 30 
minutes post-injection (95), an effect thought to be mediated via IL-6 stimulation 
of hypothalamic corticotrophin releasing factor since ACTH secretion was blocked 
by neutralising antibodies to corticotrophin releasing factor. Thus it appears that 
IL-6 may induce ACTH secretion during the acute phase response. IL-6 has also 
been shown to act synergistically with ACTH to stimulate the release of 
corticosterone from adrenal gland cells in vitro (96). Glucocorticoid has a 
synergistic effect on IL-6 induced acute phase protein synthesis (97) and also 
inhibits IL-6 production in various cells (50). Consequently, IL-6 induced 
secretion of ACTH may have a positive feedback effect on acute phase protein 
synthesis but a negative feedback effect on other aspects of the 
inflammatory/immune response. Although the above findings suggest that IL-6
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acts on the hypothalamus, other in vitro work using anterior pituitary cells raises 
the possibility that EL-6 is involved in the paracrine modulation of pituitary 
hormone secretion. Anterior pituitary cells can themselves produce IL-6 while 
IL-6 has been shown to stimulate pituitary production of growth hormone (98), 
prolactin (98,99), luteinising hormone (98,99) and follicular stimulating hormone
(99).
ACUTE PHASE RESPONSE
The acute phase response is the name given to the collection of systemic changes 
which occur in response to injury. This systemic inflammatory reaction comprises 
fever, leukocytosis, net protein catabolism, alterations in plasma steroid and metal 
concentrations and changes in the circulating concentrations of various proteins 
(the acute phase proteins), brought about by alterations in hepatic protein synthesis
(100).
In the past IL-1 and TNFa have been implicated in causing these systemic 
inflammatory effects directly (101,102). However, the principal inflammatory 
actions of these cytokines such as increased vascular permeability (103), 
chemotaxis (104), leukocyte vascular adherence (105,106), coagulation (107) and 
bacterial killing (108) occur at a local level. Moreover, IL-6 is active in the 
thymocyte assay which was previously in widespread use to measure IL-1 (109). 
Consequently, the involvement of IL-1 and TNFa in most of the systemic changes 
which comprise the acute phase response may well occur either via, or in 
conjunction with, other cytokine mediators such as IL-6, the production of which 
may be stimulated locally by IL-1 and TNFa. The recent report that anti-IL-6 
antibodies protected mice against lethal E coli infection suggests that IL-6 is pivotal 
in inducing the pathophysiological changes which occur in septic shock (110).
The evidence concerning the effect of IL-6 on plasma steroid concentrations and on 
haematopoesis has already been discussed. To date, there is no evidence that IL-6
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is involved in muscle proteolysis. Both recombinant IL-1B and TN Fa have been 
shown not to induce proteolysis or prostaglandin E2 production when incubated 
with isolated rat muscles (111). Of particular interest to this work are the reported 
actions of IL-6 with regard to acute phase protein synthesis, fever and plasma metal 
concentrations. These actions are discussed below in more detail.
Acute Phase Proteins
The principal acute phase proteins in man are shown in table 2. After trauma, 
plasma levels of these proteins increase by a variable degree. Although our 
understanding of the biological significance of these changes is limited, it is 
generally assumed that these proteins perform a protective role by limiting tissue 
damage and promoting repair and healing (100). For example, C-reactive protein 
(CRP) is an effective precipitor and agglutinin of soluble and particulate ligands, 
and may be involved in activation of the classical complement pathway (115).
As described earlier, in vitro work showed that IL-6 was identical to hepatocyte 
stimulating factor , the principal inducer of acute phase protein synthesis (20). At 
the inception of this project, this was the only evidence to suggest that IL-6 was the 
major stimulator of hepatic acute phase protein synthesis. The importance of IL-6 
as an inducer of the acute phase protein response has since been confirmed by the 
reports that it induced rat acute phase proteins in vivo in a dose-dependent 
manner(116), and that it stimulated the full spectrum of acute phase proteins in 
adult human hepatocytes (table 2). In contrast IL-1 and TNFa, previously thought 
to be important inducers of acute phase protein synthesis, failed to induce either 
serum amyloid A or CRP synthesis (112). IL-6 exerts its control on acute phase 
protein synthesis at least in part at the transcriptional level (117), and appears to 
function as an exocrine hormone rather than by an autocrine mechanism (118).
The theory that hepatocyte stimulation is one of the most important physiological 
roles of IL-6 is supported by the finding that about 30% of labelled recombinant
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Protein Magnitude of Increase in 
Serum Concentration
Stimulatory Effect of 
IL-6 on In Vitro 
Production
C-reactive protein >1000% +++ (112)
Serum amyloid A >1000% +++ (112)
a-1 Proteinase inhibitor 
(a-1 Antitrypsin)
100-1000% + (112)
a -1  Acid glycoprotein 100-1000% + (112)
a -1  Anti-chymotrypsin
100-1000% ++ (112)
Fibrinogen 100-1000% ++ (112)
Haptoglobin 100-1000% ++ (112)
C-l-Inactivator <100% + (113)
Caeruloplasmin <100% ++* (114)
♦produced by human hepatoma cells (Hep 3B)
Table 2: The principal acute phase proteins in man, and the regulation by IL-6 of 
their production by adult human hepatocytes.
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human IL-6 injected intravenously into rats was taken up by the liver by 20 
minutes post-injection (119), although after 1 hour it disappeared from the liver and 
accumulated in the skin (120). (This observation indicates that the skin may be 
involved in IL-6 catabolism).
Fever
Fever is defined as a controlled elevation of body temperature which results from a 
shift in the hypothalamic set point (121). It is thought that tissue damage/infection 
stimulates cells such as macrophages to produce a substance(s), the so-called 
“endogenous pyrogen” (EP), which induces prostaglandin E2 synthesis in the 
anterior hypothalamus resulting in a raised hypothalamic set point (121).
“Endogenous pyrogen” was the name given to a partially purified product derived 
from activated leukocytes which elicited fever when injected into animals, and 
subsequently IL-1 was thought to be equivalent to endogenous pyrogen (121). 
Certainly, numerous studies have since demonstrated that human recombinant IL- 
l a  and EL-lp elicit fever when administered either intravenously or via the 
cerebroventricles to rats and rabbits (122-127). However, it has since become 
apparent that other cytokines are capable of eliciting fever and so may qualify as 
‘endogenous pyrogen’. TNFa produces increases in body temperature when 
administered to animals (127-129), and TNFa (130), interleukin-2 (131-133) and 
interferons alpha (131) and beta (132,133) have caused fever when administered to 
humans in clinical trials.
There is now mounting evidence that IL-6 is involved in the production of fever. 
IL-6 was first implicated in causing fever by Nijsten et al who found a significant 
correlation between body temperature and IL-6 levels in 13 patients with severe 
bums (134). This report was instrumental in the decision to study the relationship 
between IL-6 and fever as part of this project. These and other workers have since 
shown that recombinant human IL-6 induced fever after administration to animals
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suggesting that IL-6 might be involved in the pyrogenic effect of IL-1 
(70,135,136). Le May et al demonstrated that intracerebroventricular injection of 
recombinant human IL-6 in rats produced a significant increase in core 
temperature, and that the plasma IL-6 concentration following injection of 
lipopolysaccharide was closely associated with the degree of fever (137). They 
concluded that IL-6 was a mediator of lipopolysaccharide induced fever. Further 
indirect support for this hypothesis was provided by the same group when they 
showed that lipopolysaccharide injected intravenously into dogs produced dose- 
dependent increases in both plasma IL-6 and rectal temperature, the peak 
temperature occurring after the peak IL-6 concentration (138).
In conclusion, evidence exists for the involvement of IL-6 in the production of 
fever, but it is still unclear whether it, or any of these other cytokines, is the major 
‘endogenous pyrogen’ of the acute phase response.
Metals
The hypercupraemia, hypozincaemia and hypoferraemia which occur during the 
acute phase response are well documented (139,140).
Hypercupraemia occurs due to increased hepatic synthesis of caeruloplasmin - a 
copper containing protein which is the principal circulating form of copper (141). 
Since IL-6 has been shown to stimulate the production of caeruloplasmin by a 
human liver tumour cell line (114), it is likely that IL-6 is a mediator of the 
hypercupraemia which occurs during the acute phase response.
Iron is transported in plasma bound to the carrier protein transferrin and in body 
secretions bound to lactoferrin (142). Non-functional iron is stored intracellularly 
in a soluble form (ferrihydroxyphosphate crystals) with ferritin - a large apoprotein 
(molecular weight 400,000 kd) which may contain up to 4500 iron atoms (143). 
Iron is essential for microbial growth, and hypoferraemia may contribute to host 
defence mechanisms by limiting the supply of available iron to invading microbes
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(144-146). Plasma iron levels reach their nadir approximately 12 hours post 
trauma (140) but the mechanism by which this occurs is still poorly understood.
Two main hypotheses have been proposed:
i. ferritin is an acute phase protein, the hepatic synthesis and plasma 
concentration of which increase during inflammation. Ferritin is thought to 
strip iron from transferrin in plasma and divert it to the liver (147-152).
ii. during inflammation, neutrophils release lactoferrin which strips iron from 
transferrin and is then selectively taken up by the cells of the reticulo­
endothelial system (153).
If the first hypothesis is correct, then IL-6 may well be involved in the production 
of hypoferraemia as a major inducer of acute phase protein synthesis, although no 
direct evidence exists that IL-6 stimulates ferritin synthesis. Several workers have 
reported hypoferraemia in animals following injection of IL-1 and TNFa (127, 
154-156). One explanation for these findings is that the effects of IL-1 and TNFa 
are mediated via IL-6. However, at present the role of IL-6 in controlling plasma 
iron concentration remains open to speculation.
Like iron, zinc is essential for microbial growth (157), and so hypozincaemia may 
confer protection on the host. Also like iron, trough levels of zinc occur 
approximately 12 hours post trauma (140). About 90% of plasma zinc is loosely 
bound to albumin. The remainder is tightly bound to alpha-2 macroglobulin and is 
metabolically unavailable (158). Metallothionein is a low molecular weight 
cytosolic protein which selectively binds heavy metals such as zinc and copper, and 
the hepatic synthesis of which increases during the acute phase response (159). 
During this response, metallothionein can extract zinc from plasma leading to 
hypozincaemia and increased hepatic zinc stores (158). Consequently, it seemed 
possible that if IL-6 were a major inducer of hepatic protein synthesis, it might well 
be involved in the production of hypozincaemia. It has been proposed that zinc
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and/or metallothionein may act as intracellular antioxidants protecting hepatocytes 
and other cells when host-generated cytotoxic oxygen species are produced in large 
amounts during infection (160-162). After this project began, strong in vitro 
evidence emerged that IL-6 stimulates metallothionein synthesis in the liver. In 
1990, Schroeder and Cousins reported that IL-6 in the presence of glucocorticoids 
regulated metallothionein gene expression by rat hepatocytes in a dose-dependent 
manner (163). Consequently, it appears probable that IL-6 is involved in causing 
hypozincaemia during the acute phase response.
SUMMARY
The biological actions of IL-6 described above and summarised in figure 1 suggest 
that IL-6 has a role in orchestrating host defence mechanisms. Injury or infection 
causes production of IL-6 which may stimulate haematopoeisis, the immune 
system, ACTH release, acute phase protein synthesis and other manifestations of 
the systemic inflammatory response.
It is likely that both IL-1 and TNFa act locally to stimulate IL-6 production during 
the acute phase response. Consequently, many of the activities previously ascribed 
to IL-1 and TNFa directly are now thought to be due to IL-1 or TNFa-mediated 
IL-6 release. Moreover, IL-6 appears to act synergistically with IL-1, TNFa and 
other cytokines. Thus it is apparent that IL-6 does not act in isolation but forms an 
important part of the cytokine network which controls the co-ordinated response of 
the body to injury.
Clinical Studies of IL-6
As it became apparent through in vitro and in vivo work that IL-6 was an important 
inflammatory mediator, attempts were made to measure it in body fluids in 
different clinical situations. While IL-1 and TNFa have also been implicated as 
important inflammatory mediators, increased circulating concentrations have not 
been detected consistently in infected patients. Increased levels of TNFa have
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Figure 1 : The principal biological actions of IL-6
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been reported in some patients with sepsis, although many more septic patients 
have been found to have undetectable levels (164-168). In general, however, high 
TNFa concentrations occurred in critically ill patients and were associated with 
poor outcome. Few of these patients had detectable plasma IL-16 concentrations 
(165,167,168). Workers have failed to detect consistent increases in plasma TNFa 
(169,170) and IL-16 (171) following surgery, although a recent report of 6 surgical 
patients described a small transient rise in plasma IL-1B post-operation (170). 
Administration of endotoxin to human volunteers was found to increase circulating 
levels of TNFa but not IL-1B (172,173).
The earliest clinical studies involving IL-6 included those of Nijsten et al who 
found elevated levels of IL-6 in the sera of patients with severe bums (134). The 
same group reported high levels in the sera and urine of patients with renal 
transplants during acute rejection episodes (174). Indeed, other workers have since 
suggested that sequential determinations of serum IL-6 may be useful in 
discriminating acute rejection from nephrotoxicity in transplant recipients (175).
Another early study by Houssiau et al reported high levels of IL-6 in the CSF of 
patients with acute central nervous system infections (176), an observation 
confirmed independently (177). Elevated levels of 11-6 have also been found in the 
CSF of patients with systemic lupus erythematosus with central nervous system 
involvement (178), but not in the CSF of patients with neurosyphilis or multiple 
sclerosis (176). Other workers reported that meningicoccal infection of the 
meninges caused an inflammatory response during the initial phase of which 
TNFa, IL-1 and IL-6 were sequentially produced (179).
Raised concentrations of IL-6 have been found in the sera of patients suffering from 
septic shock (168,180-182), and circulating concentrations of IL-6 have been 
shown to be significantly associated with plasma TNFa levels (182) and plasma 
lactate concentrations (180,181). It is likely that IL-6 has a role in the
pathophysiology of shock but whether it is directly involved in causing lethal 
complications or whether it mediates these effects indirectly remains unclear. To 
date, there are no reports of the effects of administration of anti-IL-6 antibody to 
patients with septic shock. Several studies have shown that injection of endotoxin 
into humans causes peak plasma TNF levels 60 to 90 minutes post-injection 
followed by peak IL-6 levels 2 to 3 hours post-injection (173,183,184). Other 
studies have demonstrated that patients receiving infusions of recombinant human 
TNFa develop increased levels of IL-6 in plasma peaking 3 to 6 hours post­
infusion (185,186), providing further evidence that TNFa is an important factor in 
inducing systemic IL-6 release.
More recently, Baigrie et al confirmed previous reports (169,187) when they 
reported increases in serum IL-6 concentrations following major surgery (170). 
The rise in IL-6 was preceded by a small rise in serum IL-1 concentration 
supporting the in vitro observation that IL-1 induces IL-6 synthesis.
Increased plasma levels of IL-6 have been reported in a variety of other clinical 
conditions including HIV infection (188), plasma cell dyscrasias (189,190), 
alcoholic liver disease (191), contact hypersensitivities (192) and Crohn’s disease 
(193).
Although there are now numerous reports of raised serum concentrations of IL-6 in 
patients with a wide variety of clinical conditions, most of these have been 
published in the last 3 years. They have been included in this introduction for the 
sake of completeness. At the time this project was conceived, very few clinical 
studies had been published (132,174,176) and so the nature o f the 
pathophysiological role of IL-6 in the human acute phase reponse and the clinical 
value of EL-6 as an inflammatory marker were open to question.
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AIMS
Virtually all the workers cited in this thesis have used bioassays to measure IL-6 
and, indeed, until very recently, biological assay was the only available 
methodology. Commercial immunoassay tests are now available but these are 
prohibitively expensive for large-scale studies.
IL-6 and the Acute Phase Response
By validating a bioassay, I hoped to measure IL-6 in the serum of elective surgical 
patients to assess its value as a marker of tissue damage and to determine its role in 
the metabolic response to injury. CRP has been measured extensively as a marker 
of tissue damage and inflammation although levels have not been found to be 
associated with the extent of tissue trauma (194). If IL-6 were an important 
inflammatory mediator, then surgical trauma should produce a rise in serum IL-6, 
the magnitude of which might be associated with the degree of trauma as well as 
with any subsequent change in serum CRP concentration, body temperature or 
plasma metal concentrations. Morever, I wished to study the effect of surgery on 
circulating concentrations of IL-1 (3 and TNFa.
Clinical Value of IL-6
Assuming that IL-6 proved promising as a marker of tissue damage, it was possible 
that its measurement might be useful in certain clinical situations.
SURGICAL COMPLICATIONS
It would be highly advantageous to be able to predict which surgical patients were 
liable to develop post-operative complications. It seemed likely that if serum IL-6 
were a major mediator of the systemic inflammatory response, then the occurrence 
of clinical complications in the post-operative period might be associated with 
elevated circulating IL-6 concentrations.
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SUSPECTED MYOCARDIAL INFARCTION
Myocardial infarction remains the greatest single cause of premature death in the 
United Kingdom, accounting for 35% of deaths in men, and 30% amongst women. 
The use of the available thrombolytic compounds, streptokinase (195), tissue 
plasminogen activator (196) and anistreplase (197) has been shown to reduce the 
morbidity and mortality by up to 50% in patients treated early after clinical 
presentation. The object of the use of thrombolytic therapy is to achieve coronary 
artery patency to improve left ventricular function and reduce mortality. About one 
half of all deaths after myocardial infarction are within two hours of onset, and it is 
in the early phase of presentation that the biggest impact can be achieved. Early 
introduction of therapy leads to more rapid reperfusion in a higher percentage of 
patients (198). Consequently, early diagnosis is of paramount importance and this 
has promoted much interest in serological markers of myocardial infarction. The 
tests most commonly used to diagnose myocardial infarction in the acute situation 
are total creatine kinase (CK) and creatine kinase isoenzyme MB (CKMB), but 
false negative results are common (199). Moreover, enzyme levels have been 
shown not to have independent predictive value of mortality after myocardial 
infarction (200). Patients presenting with chest pain might be expected to have 
high IL-6 levels if they had sustained significant myocardial injury, in which case 
IL-6 might prove useful in discriminating myocardial infarction from unstable 
angina in the acute situation, or as a prognostic indicator. To my knowledge, there 
are no reports in the literature concerning serum IL-6 levels during episodes of 
acute chest pain. Certainly, workers have reported increased CRP levels in 
myocardial infarction, but peak levels occurred as late as 50 hours after the event 
(201), and an earlier diagnostic aid is required if it is to influence management 
during the critical period following a suspected infarct. The aim of this study was 
to compare the value of IL-6, CK and CRP in the early diagnosis of myocardial 
infarction, and also their value as prognostic indicators by studying the association
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between these variables and left ventricular ejection fraction which has been shown 
to be an important predictor of survival in patients with coronary heart disease 
(202).
ACUTE PANCREATITIS
Another acute clinical situation where a non-specific indicator of disease severity 
could prove valuable is acute pancreatitis. Acute pancreatitis may be classified on 
clinical or morphological grounds, and usually there is good correlation between 
clinical severity and morphological severity. Clinically, mild acute pancreatitis has 
been defined as an acute condition, typically presenting with abdominal pain and 
usually associated with raised pancreatic enzymes in blood, in which there is no 
multisystem failure and an uncomplicated recovery. Severe pancreatitis is 
considered to be present if local complications develop or if one or more body 
systems become deranged. Morphologically, an attack is severe when parenchymal 
necrosis and haemorrhage is present. If only oedema is present, then the attack is 
considered to be mild morphologically (203). It is notoriously difficult to predict 
the severity of an attack at presentation. Patients with life-threatening disease may 
appear mild clinically and so not receive appropriate treatment or monitoring. 
McMahon (204) and Corfield (205) reported that the percentages of severe attacks 
correctly predicted at presentation using clinical assessment alone were a 
disappointing 39% and 34% respectively. Consequently, there is a requirement for 
a reliable test to predict severe attacks of acute pancreatitis as early as possible. 
CRP has been shown to be an indicator of disease severity (206) but its 
measurement has not been adopted widely because it is a poor discriminant during 
the first 24 hours following the onset of symptoms. Several multifactorial 
screening systems exist for severity assessment in acute pancreatitis (207-211), but 
their complexity limits their use routinely. One such system is the modified 
Glasgow system which uses 8 prognostic factors to assess disease severity (210). 
The aim of this part of the project was to determine if IL-6 might prove more useful
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as an early severity indicator than CRP or the modified Glasgow multifactorial 
scoring system.
RHEUMATOID ARTHRITIS
The aim of the final part of the project was to compare IL-6 with more conventional 
markers of disease activity in a chronic inflammatory condition such as rheumatoid 
arthritis.
The characteristic feature of rheumatoid arthritis is an inflammatory synovitis 
which is associated with cartilage destruction and bone erosions with subsequent 
joint destruction. T, and, to a lesser extent, B lymphocytes proliferate in synovial 
fluid. Hypertrophy and hyperplasia of synovial lining cells produce an invasive 
pannus which spreads to cover articular cartilage and precedes cartilage and bone 
destruction. There is now abundant evidence that cytokines play an important role 
in this inflammatory process. Firestein et al estimated the concentrations of various 
cytokines in synovial membrane affected by rheumatoid arthritis according to the 
percentage of cells positive for cytokine messenger RNA. IL-6 was found in the 
highest concentrations followed by IL-16 and TNFa (212). In contrast, cytokines 
originating from lymphocytes (interleukin-2, interleukin-3 and interferon gamma) 
were present only in low concentrations (212) or not at all (213), in spite of the 
cellular predominance of lymphocytes. Both IL-1 (214) and TNFa (215-217) have 
been detected in synovial fluid and are reported to be produced by synovial tissue 
(215,218).
In 1988, Houssiau et al reported that IL-6 was present in the synovial fluid and 
serum of patients with rheumatoid arthritis (219). This report prompted us to 
investigate the potential of serum IL-6 concentration as an inflammatory marker in 
rheumatoid arthritis.
Synoviocytes have since been shown to produce IL-6, both spontaneously and 
when stimulated by IL-1 and TNFa (49,220), and there have been further reports
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of IL-6 in the synovial fluid of patients suffering from rheumatoid arthritis and 
other inflammatory arthropathies (49,221-223). Miltenburg et al found a 
correlation between synovial IL-6 levels and clinical parameters of local 
inflammation (222). Moreover, patients with rheumatoid arthritis have recently 
been reported as having elevated serum IL-6 concentrations (223,224).
Quantitative assessment of disease activity in RA has been an elusive goal. There 
remains a need for a simple, objective test which quantitatively assesses disease 
activity and which responds quickly to changes in that activity, even before clinical 
changes are apparent. Two of the most widely used tests are ESR (225,226) and 
CRP (226,227). The main difficulty in evaluating any of these tests is the lack of a 
‘gold standard’ of disease activity against which to compare the test. In the absence 
of such a standard we chose to use the Ritchie Articular Index (228) which is 
recognised as being a good, objective, quantitative clinical assessment of the degree 
of synovitis as a reference against which to compare the value of IL-6, CRP and 
ESR as markers of disease activity in rheumatoid arthritis.
Summary
The aims of this work were as follows:
1. To validate a bioassay for the measurement of IL-6 in serum.
2. To characterise the serum IL-6, IL -lp  and TNFa responses in patients 
undergoing elective surgery of varying degrees of severity. By using elective 
surgical patients as models of controlled tissue damage, I hoped to answer the 
following questions:
(a) Does IL-6 have potential as a marker of tissue damage compared to CRP?
(b) Do IL-6, IL-lp or TNFa play a role in the following three aspects of 
the acute phase response:
(i) serum CRP response?
(ii) increased body temperature?
(iii) hypozincaemia and hypoferraemia?
To assess the value of serum IL-6 measurement in four clinical situations by 
answering these questions:
(a) Can it be used as a predictor of complications post-operation?
(b) Is it a useful diagnostic or prognostic aid in patients with suspected 
myocardial infarction?
(c) Has it any value as a severity indicator in acute pancreatitis?
(d) Has it any value as a marker of disease activity in rheumatoid arthritis?
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VALIDATION OF A BIO ASSAY FOR THE 
MEASUREMENT OF IL-6 IN SERUM
Bioassay Principle
Cells which are dependent on the presence of IL-6 for growth are incubated in 
appropriate conditions with serial dilutions of standard material or patient 
serum/plasma for a fixed time. After this incubation period the number of living 
cells present is evaluated colorimetrically, that number being dependent on the IL-6 
activity present in the standard or patient sample.
Equipment and Materials Used 
Incubator (VSL, Scotlab)
Laminar flow work unit (Gelaire, Flow Laboratories)
Adjustable micropipettes - sterilised (Gilson)
Disposable tips - sterilised (Gilson)
7TD1 cell line (Dr J Van Snick, University of Leuven, Leuven, Belgium)
Dulbeccos Modified Eagles Medium (Northumbria Biologicals Ltd)
Medium additives - Foetal calf serum (Northumbria Biologicals Ltd)
L-asparagine (Gibco Biocult)
L-glutamine (Gibco Biocult)
L-arginine (Sigma)
2-mercaptoethanol (Sigma)
Hypoxanthine/thymidine (Gibco Biocult)
Amphotericin (Gibco Biocult)
Penicillin/streptomycin (Gibco Biocult)
Hybridoma growth factor (HGF) (Janssen)
Microscope - Bactil 60 (Watson Barnet)
Counting chamber (Hawksley)
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Trypan blue (Northumbria Biologicals Ltd)
Phosphate buffered saline (PBS) without calcium and magnesium - pH 7.2 ± 0.1 - 
sterilised (Gibco Biocult)
96 flat-bottomed well microtitre plates (Cel-cult, Sterilin)
Automatic dispenser (BCL)
Multi-tip pipette (12-pette, Costar)
Recombinant human interleukin-6 (Dr L Aarden, University of Amsterdam, 
Amsterdam, The Netherlands)
P-nitrophenol-N-acetyl-p-D-glucosaminide (Sigma)
Triton-X (Scintran grade, BDH Chemicals Ltd)
MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma) 
Isopropanol (AnalaR grade, BDH Chemicals Ltd)
Sodium dodecyl sulphate (AnalaR grade, BDH Chemicals Ltd)
Hydrochloric acid (AnalaR grade, BDH Chemicals Ltd)
Microtitre plate reader (Titertek Multiskan)
Cells
CULTURE
The cells used in the assay are the IL-6 dependent mouse-mouse B cell hybridoma 
7TD1 line (30) - a generous gift from Dr Van Snick, University of Leuven, Leuven, 
Belgium. The cells are grown in an atmosphere of 8% CO2 and at a temperature of 
37°C using Dulbeccos Modified Eagles Medium (DMEM) as growth medium in 
plastic cell culture flasks. The medium is supplemented with:
10% foetal calf serum 
1.5 mM glutamine 
0.24 mM L-asparagine 
0.55 mM L-arginine 
50 fiM 2-mercaptoethanol
0.1 mM hypoxanthine
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16 pM thymidine 
Amphotericin 2.5 pg/ml 
Penicillin/streptomycin 1% volume/volume
Cells to be used in the assay are kept below a concentration of 50 x 104 cells/ml on 
the recommendation of Dr Van Snick since above this concentration cell 
responsiveness to IL-6 is reduced.
The 7TD1 cells are fed with hybridoma growth factor (HGF) at an approximate 
concentration of 400 units/ml. 50 pi added per 5 ml of cell suspension has been 
found to produce good cell growth. The growth characterisitics of the 7TD1 cells 
following addition of 50 pi of HGF (400 units/ml) to 5 ml of cell suspension 
containing approximately 4 x 104 cell per ml are shown in figure 2. Cell viability 
is determined by staining with trypan blue - failure to incorporate the dye implies 
that a cell is viable (229). Total and viable cell numbers are assessed by 
microscopy using a counting chamber. From figure 2 it can be seen that the cell 
doubling time is 15 to 20 hours. The percentage viability of 7TD1 cells is 
extremely good, being greater than 95% up to 71 hours, then falling to virtually 
zero by 138 hours.
USE IN ASSAY
When the cells are to be used in the assay, they are counted and the required 
number of cells are washed three times by centrifugation and resuspension in 
phosphate buffered saline (PBS) to remove any medium containing HGF (IL-6). 
The cells are then resuspended in medium (which contains no IL-6) at a 
concentration of 4 x 104 cells/ml. 96 well microtitre plates are prepared containing 
50 pi volumes per well of serial dilutions of standard/serum. To each well a 50 pi 
volume of cells is added (approximately 2 x 103 cells) which produces satisfactory 
numbers of cells post-incubation. Fewer than 2 x 103 cells per well result in low 
numbers of cells post-incubation and larger numbers (eg. 2 x 104 per well) give 
very high cell concentrations post-incubation with loss of sensitivity i.e. a flat dose
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Figure 2 : 7 TD1 cell growth curve.
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response curve. The plates are then incubated for 4 days at 37°C in 8% CO2 prior 
to evaluation of cell numbers.
Setting Up Plates of Standard Dilutions
Serial two-fold dilutions of standard material in assay medium are performed using 
96 well microtitre plates (8 rows x 12 columns). 100 pi of top standard is added to 
each of the 12 wells in the top row. 50 pi medium is added to all the other rows. 
50 pi two-fold dilutions are then performed (using a multi-tip pipette) down the 
eight rows starting at the top row. This produces a final volume of 50 pi in each 
well to which 50 pi of cells can be added. Thus eight different standard 
concentrations are generated and can be used to construct a dose response curve.
Standard Material
Recombinant human EL-6 was a generous gift from Dr L Aarden in Amsterdam 
(29). Dr Aarden has assigned this material a potency in units/ml - the unitage used 
in this work. He defines one unit as that amount of recombinant IL-6 which 
produces half maximal growth (measured by tritiated thymidine incorporation) in 
the B9 hybridoma cell line. The specific activity of this recombinant material is 
quoted as 106 units/pg so that 1 unit approximates to 1 pg of recombinant IL-6.
I have recently assessed the accuracy of this material’s designated specific activity 
by comparing its potency with that of the National Institute of Biological Standard 
and Controls’ (NIBSC) recombinant IL-6 of known mass concentration. 1 unit of 
Dr Aarden’s standard has the same potency in the 7TD1 bioassay as 1.4 pg of the 
NIBSC material. Thus the approximate specific activity designated, ie. 1 unit = 
1 pg, appears to be accurate.
Evaluation of Cell Numbers
My aim was to develop a colorimetric detection method. Previously, tritiated 
thymidine incorporation has been used extensively to evaluate cell numbers.
54
However, this method is cumbersome, imprecise and has the obvious disadvantage 
of necessitating handling and storage of radioisotopes. I hoped that colorimetry 
might provide a fast and reliable means of measuring cell growth.
Two types of colorimetric assay were studied. Both assays used chromogenic 
substrates to measure the activity of specific cellular enzymes. The absorbance of 
each well was measured using a Titertek Multiskan microtitre plate reader.
HEXOSAMINIDASE ACTIVITY
The first detection method involved determination of hexosaminidase 
activity (230). N-acetyl-p-D-hexosaminidase (2-acetamido-2-deoxy-p-D-glucoside 
acetamidodeoxyglucohydrolase, EC 3.2.1.30) is a ubiquitous lysosomal enzyme 
involved in the degradation of glycosylated cellular constituents. Its activity can 
be measured using the chromogenic substrate p-nitrophenol-N-acetyl-p-D- 
glucosaminide. The method is described below.
The above-named substrate was dissolved at a concentration of 7.5 mM in 0.1 mM 
citrate buffer, pH = 5. This solution was mixed with an equal volume of 0.5% 
Triton X in water and then stored at -20°C. Following a 4-day incubation period, 
cells were washed 3 times with PBS by centrifuging the plates at 250 x g for 5 
minutes for each wash to remove spent medium. If spent medium was not 
removed, the indicator phenol red present in the medium was turned yellow by the 
acid pH of the substrate causing interference with absorbance readings. The 
washing step also removed serum, which might have contained high levels of 
hexosaminidase. After washing, 60 |il of substrate solution was added to each well 
and the plates were incubated for a further 4 hours at 37°C in 8% CO2. 90 |il of 0.1 
M glycine, pH 10.4 was then added to each well to block the enzyme activity and 
develop the yellow colour reaction. Absorbance of each well at a wavelength of 
405 nm was determined using a blank reading at a wavelength of 620 nm.
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The hexosaminidase detection method as used in the IL-6 assay is summarised 
below:
1. Using 96 well microtitre plates, 2000 washed cells per well were incubated 
with serial dilutions of samples or standards for 4 days at 37°C in 8% CO2.
2. Plates were washed three times with PBS to remove spent medium and 
serum.
3. Substrate was added (60 |i/well) and plates were incubated for a further 4 
hours.
4. Reaction was blocked and yellow colour was developed by the addition of 
glycine buffer (90 |il/well).
5. Absorbance was read at 405 nm with a blank reading at 620 nm.
To assess the linearity of the hexosaminidase detection method, serial dilutions of 
7TD1 cells were performed in triplicate on 96 flat-bottomed well microtitre plates. 
Steps 2 to 5 of the above protocol were then carried out. The relationship between 
cell numbers and absorbance reading is shown in figure 3 which demonstrates a 
near linear relationship using a semi-logarithmic plot when more than 3 x 104 cells 
are present per well.
Figure 4 shows the dose response curve obtained when serial dilutions of 
recombinant EL-6 were assayed as per the above protocol. A semi-logarithmic plot 
gives a sigmoid shaped curve with an acceptable slope and with the linear portion 
extending over 0.4 absorbance units. The flattening out at the top of the curve 
indicates that maximal cell growth has been achieved.
Thus, the hexosaminidase method produces a satisfactory dose response curve. 
However, a major problem of this detection system is the limitation to sample
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Figure 3 : 7 TD1 cell dilution curve using the hexosaminidase detection method.
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throughput caused by the washing steps which are both time consuming and labour 
intensive.
DEHYDROGENASE ACTIVITY
The curtailment of sample throughput by the washing steps in the hexosaminidase 
method prompted me to look at more convenient methods. One such method 
measures dehydrogenase activity to evaluate cell numbers using the tetrazolium 
salt, MTT (3-(4, 5-dimethylthiazol-2-yl) - 2, 5-diphenyl tetrazolium bromide), as a 
chromogenic substrate (the action of dehydrogenase turns the yellow MTT salt 
purple) (231). The tetrazolium ring is cleaved by dehydrogenase enzymes in active 
mitochondria and so the reaction occurs only in living cells. After incubation with 
MTT, a detergent is added to produce uniform colour formation. MTT is made up 
at a concentration of 5 mg/ml in PBS and filtered to sterilise prior to use. No 
washing steps are required.
Three possible detergents were evaluated using the protocol shown below. The 
detergents used were acidified isopropanol (231) 10% sodium dodecyl sulphate 
(SDS) in 0.04 M HC1 and 10% Triton-X in 0.5 M HC1 (232).
1. Using 96 well microtitre plates, 2000 washed cells (50 p.1) per well were 
incubated with serial dilutions of sample or standard (50 |il) for 4 days at 
37°C in 8% C 02.
2. 10 |il of MTT (5 mg/ml in PBS) was added to each well and plates were 
incubated for a further 4 hours.
3. 50 |il of detergent was added to each well.
4. Absorbance was read at 540 nm with a blank reading at 690 nm.
Acidified isopropanol was found to cause turbidity by precipitating serum proteins. 
When it was added to wells containing 15 different sera at dilutions similar to that
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used in the IL-6 assay but containing no cells, absorbance readings obtained ranged 
from 0.183 to 0.341, median 0.276. Thus patient samples were producing falsely 
elevated absorbance readings when acidified isopropanol was used as a detergent.
Similar experiments conducted using both Triton-X and SDS as detergents 
demonstrated negligible contribution to absorbance by serum at similar dilutions to 
that used in assay. Thus neither serum protein precipitation nor interference caused 
by dehydrogenase activity present in serum appeared to be a problem when MTT 
was used with either SDS or Triton-X as detergent.
To assess linearity of the MTT/SDS and MTT/Triton-X detection methods, serial 
dilutions of 7TD1 cells were performed and steps 2 to 4 of the above protocol were 
carried out. Solubilisation and colour formation with both methods were better 
when the plates were left for approximately 16 hours at room temperature 
following detergent addition. Thus absorbance readings were made after plates had 
been left overnight.
The relationship between cell numbers and absorbance is illustrated in figure 5. 
Both plots demonstrate near linearity but the sensitivity of the MTT/Triton-X 
detection system appears superior to that of MTT/SDS. Consequently the 
MTT/Triton X system was chosen to evaluate cell numbers and adopted in the final 
assay protocol.
Optimal Incubation Time
Following addition of the 7TD1 cells, the assay plates are incubated for a fixed 
period of time at 37°C in 8% CO2.
In order to determine the optimal incubation period, 3 identical plates were set up, 
each containing 12 x8  serial dilutions of recombinant IL-6. Following the addition 
of the 7TD1 cells, one plate was incubated for 3 days, one for 4 days and one for 5
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days. The number of cells present at the end of each incubation period was 
evaluated colorimetrically and the resulting dose response curves plotted for the 3 
plates (figure 6). The 3 days curve remains flat. The 4 and 5 days curves both have 
acceptable sensitivities although the 5 days curve flattens out at a lower dose than 
the 4 days curve. Thus, because the 4 days curve had a larger linearity range than 
the 5 days curve and because it was preferable to have as short an incubation stage 
as possible, 4 days was chosen as the assay incubation period.
Samples
COLLECTION
Blood may be collected in either a plain or lithium heparin tube as serum and 
heparinised plasma have been found to give equivalent results in the assay (table 3). 
EDTA plasma should not be used as it was found to inhibit cell growth (table 4).
STABILITY
Blood should be separated as soon as possible after collection to minimise any in 
vitro IL-6 production, although I have found that the IL-6 activity in serum left for 
up to 6 hours before separation from blood cells does not differ from that in serum 
separated immediately.
Serum/plasma samples may be stored at 4°C for at least 4 days with no loss of IL-6 
activity (table 5a). Frozen samples may be stored at -20°C for at least 7 months 
with no loss of IL-6 activity (table 5b).
INHIBITORS
It was noted that the serum dilution dose response curve seen when serum dilution 
factor was plotted against absorbance reading exhibited a hook effect, i.e. higher 
concentrations of serum (lower dilutions) produced lower absorbance readings in
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IL-6 concentration (units/ml)
Sample Serum Heparinised Plasma
1 18 20
2 <14 <14
3 552 597
4 364 335
5 204 203
6 <14 <14
7 84 98
8 154 150
9 28 29
10 578 558
11 426 412
12 84 99
13 106 108
14 94 97
15 395 363
t = -0.07; p = 0.94, paired t-test
Table 3: Comparison of IL-6 results obtained from serum and heparinised plasma. 
Each pair consists of aliquots from the same blood sample
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Absorbance
Sample Serum (1/4 dilution) EDTA Plasma (1/4 
dilution)
1 0.042 0.040
2 0.288 0.066
3 0.646 0.061
Table 4: Examples of the effect of EDTA plasma on cell proliferation 
determined colorimetrically.
Each sample was divided into EDTA anticoagulated and clotted tubes 
and then separated. Serum and EDTA plasma were assayed together.
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IL-6 concentration (units/ml)
Serum Baseline After storage for four 
days at 4°C
1 28 27
2 464 420
3 244 256
4 1845 1892
5 224 196
6 1094 1158
t = -0.02; p = 0.98, paired t-test
IL-6 concentration (units/ml)
Serum Baseline After storage for 7 
months at -20°C
1 529 537
2 125 134
3 112 105
4 64 48
5 258 295
6 112 105
t = -0.04; p = 0.97; paired t-test
Tables 5a and 5b: Effect of storage on IL-6 activity in serum.
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the assay (figure 7). This was thought to be due to the presence of inhibitors in 
serum which might be inhibiting cell growth either specifically or non-specifically.
The experiment described below was performed to determine if this effect could be 
abolished by heating serum prior to analysis.
Serum from a healthy volunteer was divided into two aliquots and one aliquot was 
heated for 30 minutes in a waterbath at 56°C. (This procedure has been 
recommended by Dr Aarden as a method for removing inhibitors which did not 
influence IL-6 activity (174)). A fixed amount of IL-6 standard was added to wells 
containing varying dilutions of both the heated and unheated aliquots of serum. 
The plate was then analysed and the absorbance of each well measured (table 6). 
The degree of dilution of heated serum did not affect the absorbance readings 
obtained for the fixed amounts of EL-6. However, it was apparent that the presence 
of unheated serum in the assay inhibited cell growth (confirmed by microscopy) 
and produced very small absorbance readings. This inhibitory effect of unheated 
serum did not disappear until serum was present at a dilution factor of 1 in 128 or 
more.
This experiment supported the hypothesis that serum contains factors inhibiting 
EL-6 dependent cell growth which can be destroyed by heating. Consequently all 
plasma/serum samples are heated for 30 minutes at 56°C prior to analysis.
PREPARATION OF SAMPLES FOR ANALYSIS
Either serum or heparinised plasma may be used. 25 |il of sample is added to each 
of the 12 wells in the top row of a 96 well microtitre plate. 75 jil of medium is also 
added to each well in the top row producing a 1 in 4 dilution of serum. Thereafter 
50 |il of medium is pipetted into all the other wells in the plate. 50 |il twofold 
dilutions are then performed starting from the top row down the eight rows on the 
plate. Consequently each of the twelve 8-well columns on a plate contains eight
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Figure 7 : Dose response curve of unheated serum showing hook effect.
Absorbance when 
serum  not heated
Serum dilution Absorbances when 
serum heated
0.07 1 in 2 0.53
0.08 1 in 4 0.54
0.07 1 in 8 0.52
0.05 1 in 16 0.52
0.12 1 in 32 0.47
0.42 1 in 64 0.57
0.54 1 in 128 0.51
Table 6 : Effect of heating serum on absorbance readings in IL-6 assay. 
Each well contains a fixed amount of IL-6
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two-fold dilutions of serum, ranging from 1 in 4 to 1 in 512. All samples are run in 
duplicate and so every sample analysed generates 16 assay points (8 dilutions in 
duplicate).
This sample dilution process is essential in order to obtain a detection signal which 
can be read off the standard curve, and to demonstrate parallelism of sample and 
standard dose response curves (page 73).
Final IL-6 Assay Protocol
1. Duplicate serial dilutions of serum (starting at 1 in 4 dilution) and standard
(top standard concentration = 1 0 0  units/ml) are carried out in 96 well 
microtitre plates giving a volume of 50 pi/well.
2. 50 pi containing approximately 2 x 103 washed 7TD1 cells are added to
each well.
3. Plates are incubated for 4 days at 37°C in 8% CO2.
4. 10 pi MTT (5 mg/ml in PBS) is added to each well.
5. Plates are incubated for a further 4 hours at 37°C in 8% CO2.
6. 50 pi Triton-X (10% in 0.5 M HC1) is added to each well.
7. Plates are left at room temperature overnight.
8. Absorbances are read at a wavelength of 540 nm with a blank reading at
690 nm.
Plate 1 shows a microtitre plate which has reached step 8 of the above protocol. 
Figure 8 shows the sigmoid shaped dose response curve obtained when the final 
assay protocol described above is followed. The curve is linear from about 0.1 to
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Plate 1 : 96 well microtitre plate which has been analysed according to the final
IL-6 assay protocol and is ready for the absorbance of each well to be 
read.
The first eight columns contain serial dilutions o f recom binant IL-6 
standard starting from the top row. The wells in the last four columns 
contain medium only (reagent blanks).
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0.5 absorbance units and flattens out thereafter indicating that maximal cell growth 
occurs at an EL-6 concentration of less than 50 units/ml.
Blanks
SERUM
Originally, all samples were analysed in triplicate, the third test being used as a 
sample blank (50 |il medium added instead of 50 (il of cells). Blank absorbances 
including those from icteric and haemolysed samples were low (<0.05) and were 
unaffected by the degree of serum dilution - suggesting that these blanks 
represented background absorbance. This was accounted for by the use of reagent 
blanks and so sample blanks were dispensed with.
REAGENT
Reagents blanks are run in every assay. These are prepared by adding 50 |il of 
washed cells to 50 p.1 medium (instead of sample). After incubation, virtually no 
living cells should be visible by microscopy. Following MTT/Triton-X addition, 
absorbances should be less than 0.05, reflecting background absorbance. 
Absorbances greater than 0.1 or significant numbers of cells on microscopy imply 
that the cells have lost their dependence on IL-6 (or have not been washed 
properly) thus invalidating the assay.
Reagent blank absorbances are subtracted from mean absorbance value for each 
sample/standard duplicate.
Calculation of Unknown Results
All serum/plasma samples are set up in duplicate at 8 different dilutions (twofold 
from 1 in 4 to 1 in 512). The initial dilution of 1 in 4 was chosen to minimise any 
possible serum effects and because I had found that serum present at this dilution 
caused no interference with the assay detection method (page 59).
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Serial dilutions of patient samples are necessary for two reasons: firstly, to 
demonstrate parallelism with the standard curve; secondly, to obtain absorbance 
readings from at least 2 different sample dilutions which may be read from the 
linear portion of the standard curve. Failure to demonstrate parallelism between 
sample and standard material invalidates the IL-6 results obtained since factors 
other than IL-6 in such samples would thus appear to be stimulating cell growth. 
Only by performing multiple dilutions of all samples is one likely to obtain several 
absorbance readings on the linear portion of the standard curve.
A standard curve is constructed by plotting log IL-6 concentration against 
absorbance. Absorbances obtained from 2 or ideally 3 different dilutions of each 
sample run in duplicate (4 or 6 assay points) are averaged for each duplicate and the 
blank subtracted. The resulting mean absorbance value for each sample dilution is 
then read from the standard curve and the resulting IL-6 concentration multiplied 
up according to the appropriate dilution factor. These concentrations are then 
averaged to give the IL-6 concentration in units/ml.
Figure 9 shows the dilution curves for 3 patient sera which exhibit acceptable 
parallelism with the recombinant IL-6 standard curve. In each case, the top 3 
absorbance values are read from the standard curve and the mean of the resulting 
concentrations (after correction for dilution) is used to provide the IL-6 
concentration in each sample.
Quality Control
Two pools of patient sera (high and low) were heated and frozen to be used as 
control material. These QCs are run in every assay at intervals of approximately 20 
samples. QC results are discussed in the ‘Assay Parameters’ section (page 75).
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Figure 9 : Parallelism of patient sera and recombinant EL-6 dose response curves.
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Assay Param eters 
IMPRECISION
High and low control materials were analysed in twenty consecutive assays 
performed over a two month period. Overall assay imprecision was calculated 
using all the high QC results and all the low QC results. Each QC result was 
determined from a minimum of 4 assay points. The low QC results had a CV of 
19% (n = 32, mean = 75.7, SD = 14.7 units/ml), and the high QC results had a CV 
of 23% (n = 26, mean = 1426, SD = 327 units/ml). Thus overall assay imprecision 
is approximately 20% - unacceptably high for more conventional assays, but a 
satisfactory level of imprecision for a bioassay (233,234).
SPECIFICITY
Assay specificity was confirmed in three ways.
First, serial dilutions of samples were performed to demonstrate parallelism with 
the standard dose response curves (page 73). Parallelism makes assay specificity 
more likely.
Second, recombinant IL -la , IL-l(3,TNFa and interleukin-2 were also used to test 
specificity. No cell growth resulted from the use of these materials in assay at high 
concentrations (0.75 mg/ml, 1.7 mg/ml, 1 |ig/ml and 20 units/ml respectively).
Third, rabbit polyclonal anti-human IL-6 antiserum heated for 30 minutes at 56°C 
to remove non-specific cytotoxicity was used in the IL-6 assay. 50 |il of antiserum 
at a dilution of 1 in 300 was added to wells containing either sample or standard 
material. In all cases the addition of antiserum abolished cell growth. The dose 
response curves of 2 patients’ samples in figure 10 illustrate the effect of the 
addition of antiserum.
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RECOVERY
Recovery experiments performed by adding 100 units/ml of IL-6 to different 
patient samples gave recovery values ranging from 86% to 129%.
ACCURACY
Accuracy is a function of specificity and standardisation. Specificity is discussed 
above and the evidence indicates that the assay is specific. Standardisation is 
discussed earlier in the section ‘Standard Material’ (page 53). Calibration against 
the IL-6 standard from the NIBSC did suggest that the designated specific activity 
of our standard material is accurate. However, no external quality control material 
is yet available to assess accuracy.
WORKING RANGE
The working range of the assay is 14 to 5000 units/ml based on a standard curve 
linear from 3.5 to 10 units/ml (figure 8) and sample dilutions from 1 in 4 to 1 in 
512.
REFERENCE RANGE
IL-6 was measured in serum from 20 healthy volunteers. The range of results 
obtained was <14 to 18 units/ipl, the median being <14 units/ml.
Summary
A bioassay for the measurement of IL-6 in serum which uses colorimetry to 
evaluate cell proliferation has been validated. The colorimetric detection system 
chosen involves the use of MTT as a substrate for dehydrogenase activity, and 
Triton-X as a detergent. This system is preferable to the colorimetric determination 
of hexosaminidase activity because it requires no washing steps. Addition of MTT 
and Triton-X to 1000 assay points (approximately 10 plates) each takes less than 10
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minutes. In contrast, the washing steps necessary prior to the addition of 
hexosaminidase substrate to 10 plates take well over an hour.
The simplicity of the MTT/Triton-X detection system also compares favourably 
with tritiated thymidine incorporation. Following incubation with tritiated 
thymidine, cells are harvested and added to counting vials with scintillation fluid. 
The harvesting process takes up to 10 minutes per plate, is exceedingly operator- 
dependent and requires a harvester. To count each assay point using tritiated 
thymidine incorporation takes in excess of 1 minute (usually 3 minutes) whereas 
the Titertek Multiskan takes approximately 1 second to read each assay point. 
Furthermore, few laboratories have beta counting facilities available. In terms of 
reagent cost, the MTT/Triton-X detection system compares extremely well - 78 
pence per 1000 assay points as against £34.00 per 1000 assay points using tritiated 
thymidine.
The bioassay described here performs well in relation to other bioassays with 
respect to reproducibility. MTT/Triton-X evaluation of cell numbers is fast, 
simple and economic. Either serum or heparinised plasma may be used - the 
minimum volume required is 60 pi. It takes approximately 3 hours for one person 
to set up an assay of 100 serum samples and the assay turnaround time is 5 days.
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METHODS 
STUDY DESIGN
IL-6 and the Acute Phase Response
PATIENTS
The project was approved by the Ethical Committee of the Royal Infirmary, 
Glasgow, and informed consent was obtained from all patients taking part in the 
study.
39 patients in 6 broad surgical categories were studied prospectively between 
February 1988 and July 1989 (table 7). No patient was on drug treatment known 
to affect the acute phase response. Patients underwent routine general anaesthesia: 
pre-medication with papaveretum or temazepam; anaesthesia with thiopentone, 
suxamethonium or vecuronium, nitrous oxide, enflurane or halothane, atropine, 
neostigmine; post-operative analgesia with morphine or papaveretum. All of these 
agents were received by patients in each surgical category with the exception of 
halothane which was not given to any patients in the minor surgery or vascular 
surgery groups.
CLINICAL
Each patient’s post-operative clinical course was monitored for the development of 
complications. Axillary temperatures were recorded from the routine temperature 
charts.
Patients were classified as complicated or uncomplicated retrospectively. Patients 
were considered to have had complicated post-operative courses if their axillary 
temperature increased above 38°C, or if they developed clinical problems in the 
first seven days post-operation. In the absence of these, they were considered
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Surgical Category Number of Patients
Minor (varicose veins, lumpectomy, thyroidectomy) 7
Moderate abdominal (vagotomy, cholecystectomy) 7
Hip replacement 6
Colorectal 11
Vascular (aneurysm resection, bypass grafts) 6
Major vascular (aneurysm resection plus aortic 
bifurcation graft)
2
Total 39
Table 7: Elective surgical patients studied in ‘EL-6 and Acute Phase Response’ 
study.
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to have made uncomplicated recoveries. Only patients who made uncomplicated 
recoveries were included for the purpose of studying the acute phase response.
SAMPLES
Venous blood samples were collected from each patient prior to surgery and at 2- 
hourly intervals until 6 hours (hourly in certain patients), 8-9 hours, 12 hours, 24 
hours, 48 hours, 72 hours and 96 hours post-incision. Samples were separated and 
sera stored at -20°C prior to analysis for IL-6, CRP, IL-lp, TNFa, iron, transferrin, 
zinc and albumin.
ASSAYS
IL-6 was measured in all samples using the bioassay described in the Chapter 
‘Validation of a Bioassay for the Measurement of IL-6 in Serum’ (page 49).
CRP was measured in all samples by fluorescence polarisation immunoassay 
(TDX, Abbot, Nottingham, Berks, UK) which had a detection limit of 10 mg/1 and 
a CV of less than 5%.
IL-16 was measured in samples from the first fifteen patients studied (none of 
whom developed complications) using an enzyme linked immunosorbent assay 
(Interleukin-lp ELISA kit, Cistron Biotechnology, Pine Brook, New Jersey, USA) 
which had a detection limit of 20 pg/ml.
TNFa was measured in samples from the first fifteen patients studied using an 
immunoradiometric assay (TNFa IRMA, Medgenix Diagnostics, Brussels, 
Belgium) which had a detection limit of 14 pg/ml.
Iron and transferrin were measured in samples taken prior to surgery and at 12 
hours and 48 hours post-surgery from 22 patients who made uncomplicated 
recoveries post-operation. Transferrin was measured by immunoturbidimetry using 
antisera and standard from Atlantic Antibodies (Maine, USA) and the Encore
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Chemistry System (Baker Instruments, Windsor, Berkshire, UK) (CV less than 
7.5%), and iron was measured by colorimetric assay (Ferrozine) on a Hitachi 704 
analyser (Boehringer Mannheim, Germany).
Zinc and albumin were measured in samples taken prior to surgery and at 12 hours 
and 48 hours post-surgery from 25 patients who made uncomplicated post­
operative recoveries. Zinc was measured by atomic absorption spectrometry and 
albumin was measured by bromocresol green colorimetric assay on a BM Hitachi 
704 analyser.
OUTCOMES
The time course and magnitude of the responses of serum IL-6, TNFa, and IL-1B 
to surgery were compared and related to the serum CRP response and to the 
changes in body temperature which occurred. The magnitude of each response was 
determined by measuring the area under the response curve.
Iron and zinc are mostly bound to transferrin and albumin respectively in serum. 
Since serum concentrations of both transferrin and albumin decrease during the 
acute phase response, iron/transferrin and zinc/albumin ratios were calculated to 
correct for any changes in iron and zinc concentration which occurred due to 
decreases in concentrations of their binding proteins. Iron and zinc concentrations 
reach their nadir approximately 12 hours post-incision (140). The associations 
between decreases in iron/transferrin and zinc/albumin ratios during the first 12 
hours post-incision and serum IL-6 response were studied.
Moreover, in order to study the temporal relationship between changes in serum IL- 
6 concentration and changes in iron/transferrin and zinc/albumin ratios, the IL-6 
responses in 5 uncomplicated cholecystectomy patients were related to changes in 
the iron/transferrin ratio and zinc/albumin ratio which occurred following surgery 
in 9 different cholecystectomy patients previously studied by our group (140).
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Clinical Value of IL-6 
SURGICAL COMPLICATIONS
IL-6 and CRP responses in surgical patients who were classified retrospectively as 
complicated were related to their clinical course, and serum IL-6 and CRP 
concentrations in patients with complications were compared with those in patients 
who did not develop complications.
SUSPECTED MYOCARDIAL INFARCTION
Patients
The project was approved by the Ethical Committee of the Royal Infirmary 
Glasgow, and informed consent obtained from all patients.
15 patients admitted to hospital with suspected myocardial infarction were studied 
prospectively between January and June of 1989. All patients were seen at 
presentation by a cardiologist who made the diagnosis of suspected or probable 
myocardial infarction.
Clinical
The time between the onset of symptoms and presentation was recorded as was the 
clinical course. The diagnosis of myocardial infarction or unstable angina pectoris 
was made retrospectively based on the WHO criteria (235).
Left ventricular performance was assessed on the third hospital day. Apical biplane 
cross-sectional echocardiography was performed and a Simpson’s rule algorithm 
used to calculate end-diastolic volume and end-systolic volume (236) from which 
the left ventricular ejection fraction (LVEF) was calculated.
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Samples
Venous blood was taken on admission from each patient. Samples were separated 
and stored at -20°C prior to analysis for IL-6 and CRP. Serum was also stored at 
4°C and CK activity measured the following day.
Assays
IL-6 and CRP were measured as described previously.
CK was measured, using an enzymatic assay (CK NAC activated, Boehringer 
Mannheim, Germany) on a Hitachi 737 analyser (Boehringer Mannheim, 
Germany).
Outcomes
Admission serum IL-6, CRP and CK concentrations in patients with unstable 
angina were compared with those in patients who had myocardial infarctions. 
Moreover, the associations between these three variables and left ventricular 
performance as assessed by LVEF were studied.
ACUTE PANCREATITIS
Patients
The project received Ethical Committee approval and informed consent was 
obtained from all patients.
23 patients admitted with acute pancreatitis were prospectively entered into the 
study between December 1987 and July 1989. The diagnosis of acute pancreatitis 
was made on the basis of a serum amylase greater than 720 IUA in the presence of a 
compatible clinical picture.
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Clinical
The delay between the onset of symptoms and presentation was noted. The clinical 
course of the disease and a modified Glasgow score were recorded for each patient 
(One point was scored for each of the 8 prognostic factors shown in table 8 present 
during the 48 hours following admision. A score of three or more suggests a 
severe attack of pancreatitis (210)).
Definitive classification of disease severity was performed retrospectively 
depending upon the clinical outcome. Patients were considered to have had a 
severe attack if one or more of the following was present: pancreatic pseudocyst; 
pancreatic sepsis; respiratory failure (pC>2 < 8 kPa requiring oxygen for more than 5 
days or assisted ventilation); renal failure (urine output less than 400 ml per 24 
hours despite adequate fluid replacement); shock (systolic blood pressure less than 
90 mmHg in the presence of an adequate circulating volume); hospital stay of more 
than 14 days (unless discharge was delayed for cholecystectomy or for social 
reasons); or death. If none of these was present, then the patient was considered to 
have suffered a mild attack.
Samples
Venous blood samples were taken on admission, 6-hourly for 48 hours and then 
twice daily for a further 3 days. Samples were separated and stored at -20°C prior 
to analysis for IL-6 and CRP.
Assays
IL-6 and CRP were measured as previously described in all samples from the 23 
patients. Amylase was measured using an enzymatic assay ( a  amylase PNP, 
Boehringer Mannheim, Germany) on a BM Hitachi 737 analyser.
Arterial partial pressure of oxygen <8.0 kPa
Serum albumin <32 g/1
Semm calcium <2.0 mmol/1
White cell count >15 x 109/1
Aspartate transaminase (AST) >200IU/1
Lactate dehydrogenase (LDH) >600 IU/1
Plasma glucose >10 mmol/1 (in the absence of diabetes 
mellitus)
Semm urea >16 mmol/1
Table 8: The modified Glasgow criteria for severity prediction in acute 
pancreatitis. A severe attack is indicated by the presence of 3 or more 
criteria.
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Outcomes
Serum concentrations of IL-6 and CRP following admission and modified Glasgow 
scores were compared between those patients classified as having mild disease and 
those classified as having severe disease.
RHEUMATOID ARTHRITIS
Patients
33 patients with rheumatoid arthritis who attended a rheumatology out-patient 
clinic at Glasgow Royal Infirmary were studied.
Clinical
Disease activity was scored using the Ritchie Articular Index (228).
Samples
Venous blood from each patient was collected into Westergren and clotted tubes. 
The clotted samples were separated and sera stored at -20°C prior to analysis for 
IL-6 and CRP.
Assays
IL-6 and CRP were measured as described previously. ESR was measured by 
Westergren’s method (237).
Outcomes
The associations between serum IL-6, CRP and ESR and clinical disease activity as 
measured by the Ritchie Articular Index were studied.
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DATA ANALYSIS AND PRESENTATION
Results are expressed as median and range throughout this work. Statistical 
analyses have been performed using MINITAB statistical softwear (Minitab Inc, 
Pennsylvania, USA).
The Mann Whitney test has been applied to test differences between groups, and 
the W statistic (the sum of the ranks corresponding to the observations in the first 
sample), p value and 95% confidence interval (Cl) for differences are quoted.
Associations between variables have been studied using the Pearson product 
moment correlation coefficient (r) and linear regression analysis. The regression 
equation is presented as y = a + bx along with the values of t and p for the null 
hypothesis that b does not equal 0 ie, that there is statistically significant evidence 
of an association between the variables x and y. Where appropriate the 95% 
confidence interval for the value of b is also quoted.
For the sake of clarity, error bars in line graphs have been omitted, and these graphs 
are used only to illustrate time courses. Where differences between groups have 
been analysed, data points are presented in the form of scatter plots. Likewise, 
most associations between variables are presented in the form of scatter plots 
showing the regression line.
Diagnostic sensitivity of a test is calculated as
the number of true positive results x 100% 
number of people with the disease
Diagnostic specificity of a test is calculated as
the number of true negative results x 100% 
number of people without the disease
Positive predictive value of a test is calculated as
the number of true positive results x 100% 
total number of positive results
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Negative predictive value of a test is calculated as
the number of true negative results 
total number of negative results
Efficiency of a test is calculated as
the number of true results 
the total number of results
x 100%
x 100%
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RESULTS 
IL-6 and the Acute Phase Response
Of the 39 elective surgical patients studied, 29 made uncomplicated recoveries 
post-operation (table 9). Of these, one medical student who underwent partial 
thyroidectomy has been excluded from the minor group because her surgery which 
was particularly painstaking was not representative. The remaining 28 patients 
have been used as models to study the role of IL-6, TNFa and IL-1 in the acute 
phase response.
The duration of surgery in the minor group was shorter than that in the other 5 
groups (table 10). The moderate group tended to have shorter operations than the 
more major groups but the differences failed to meet statistical significance. There 
was considerable overlap in duration of surgery among the 4 more major surgical 
groups.
None of the first 15 patients studied had detectable serum levels of either TNFa or 
IL-18 at any time post-surgery.
Serum IL-6 rose within 2 to 4 hours of incision in all 28 patients, peaking at 6 to 12 
hours post-incision (slightly later in the hip surgery patients) (figure 11). The 
magnitude of the IL-6 response (measured as the area under the response curve up 
to 48 hours post-incision) differed among the various surgical groups (table 11, 
figure 12). Patients undergoing minor procedures had a significantly smaller 
response than any of the other patients. Similarly, the moderate abdominal group 
demonstrated a significantly smaller IL-6 response than the 4 more major surgical 
groups. Considerable overlap existed among the responses of the hip, vascular and 
colorectal groups. Peak IL-6 levels were closely associated with integrated IL-6 
response (figure 13) (r = 0.95, y = -78.2 + l.lx , t = 15.12, p <0.001, 95% Cl = (1.0, 
1.2)) and so may be considered to be representative of the overall response.
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Number of patients having:
Surgical Category Uncomplicated Recovery Complicated Recovery
Minor 6 0
Moderate 5 2
Hip 6 0
Colorectal 6 5
Vascular 4 2
Major Vascular 1 1
Total 28 10
Table 9: Post-operative course in 38 of the 39 surgical patients studied (one
patient has been excluded from the minor group (see text)).
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Surgical Category Duration of Surgery (minutes)
Minor (n = 6) 45 (15-55)a
Moderate (n = 5) 75 (45 - 135)b
Hip (n = 6) 120 (60 - 190)c
Vascular (n = 4) 85 (75 - 160)d
Colorectal (n = 6) 110 (75 - 270)e
Major Vascular (n = 1) 225
a<b, W = 24.0, p = 0.034, 95% Cl = (-90, 0) 
a<c, W = 21.0, p = 0.008,95% Cl = (-90, -15) 
a<d, W = 21.0, p = 0.013, 95% Cl = (-115, -30) 
a<e, W = 21.0, p = 0.005, 95% Cl = (-215, -30)
(all differences tested using Mann Whitney test)
Table 10: Duration of surgery in 6 surgical categories.
Results are expressed as median (range).
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Figure 11 : Serum IL-6 response to 6 categories of elective surgery.
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Surgical Category Area under IL-6 
response curve 
up to 48 hours 
post-incision*
Peak serum IL-6 
concentration (units/ml)
Minor (n = 6) 46 (35-54)a 36 (28-46)
Moderate (n = 5) 164 (76 - 210)b 130 (56 - 225)
Hip (n = 6) 291 (246 - 681)c 208 (122 - 395)
Vascular (n = 4) 367 (262 - 628)d 272 (192 - 527)
Colorectal (n = 6) 562 (438 - 1500)e 569 (346 - 2000)
Minor (n = 1) 1292 1220
* One unit of area is equivalent to 20 units/ml.hour.
a<b, W = 21.0, p = 0.008, 95% Cl = (-164, -30) 
a<c, W = 21.0, p = 0.005, 95% Cl = (-627, -205) 
a<d, W = 21.0, p = 0.014, 95% Cl = (-582, -216) 
a<e, W = 21.0, p = 0.005, 95% Cl = (-1446, -404) 
b<c, W = 15.0, p = 0.008, 95% Cl = (-490, -63) 
b<d, W = 15.0, p = 0.020, 95% Cl = (-548, -70) 
b<e, W = 15.0, p = 0.008, 95% Cl = (-1308, -274)
(all differences tested using Mann Whitney test)
Table 11: IL-6 response and peak serum IL-6 concentration in 6 surgical 
categories.
Results are expressed as median (range).
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Figure 12 : Comparison of the magnitude of the serum IL-6 response among 6 
surgical categories.
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Figure 13 : The association between integrated IL-6 response and peak serum IL- 
6 concentration in 28 surgical patients.
(r = 0.95, y = -78.2 + 1.1 x, p <0.001)
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The differences in IL-6 response among the surgical categories prompted me to 
examine the relationship between integrated IL-6 response over 48 hours and the 
length of operation (intended to reflect the degree of tissue trauma sustained during 
surgery). Figure 14 illustrates the highly significant correlation between 
integrated IL-6 response and length of operation (r = 0.85, y = -139.0 + 5.1x, t = 
8.37, p <0.001, 95% Cl = (3.9,6.4)) which does suggest that the overall response is 
related to magnitude of tissue damage. As expected, peak IL-6 levels were also 
closely associated with the duration of surgery (r = 0.81, y = -231.0 + 5.7x, t = 7.0, 
p <0.001, 95% Cl = (4.1, 7.3)) and may therefore be considered to reflect extent of 
injury.
Figure 15 shows the CRP response to surgery in the six surgical categories. Unlike 
IL-6, there was no detectable increase in CRP in the group of minor surgical 
patients. In the other four groups, CRP rose 8 to 12 hours post-incision peaking 24 
to 48 hours post-incision. However, no significant differences were observed in 
integrated CRP responses 12 to 72 hours post-incision among these four groups 
(figure 16). As was the case for IL-6, there was good correlation between peak 
CRP and integrated CRP response (r = 0.96, y = 8.0 + 0.5x, t = 17.81, p<0.001, 
95% Cl = (0.4, 0.6)). The integrated CRP response was less closely associated 
with length of operation (figure 17) (r = 0.63, y = 76.4 + 1.8x, t = 4.12, p <0.001, 
95% Cl = (0.9, 2.7)) than was the integrated IL-6 response.
Figures 18a-d illustrate the temporal relationship between serum IL-6 and CRP 
responses in 4 of the 6 surgical groups. The minor and major vascular groups are 
not shown since there was no CRP response in the former, and the latter consisted 
of only 1 patient. In general, IL-6 and CRP responses follow the same pattern with 
peak CRP levels occurring 20-40 hours after peak IL-6 levels. The integrated 
IL-6 response was associated weakly but significantly with the integrated CRP 
response (figure 19) (r = 0.63, y = 143.0 + 0.3x, t = 4.15, p <0.001, 95% Cl = 
(0.2, 0.4)).
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Figure 14 : The association between duration of surgery and integrated IL-6 
response in 28 surgical patients.
(r = 0.85, y = -139.0 + 5.1 x, p <0.001)
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Figure 15 : Serum CRP response to 6 categories of elective surgery.
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Figure 16 : Comparison of the magnitude of the serum CRP response among 6 
surgical categories.
(5 of the 6 minor patients had no detectable CRP response)
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Figure 17 : The association between duration of surgery and integrated CRP 
response in 28 surgical patients.
(r = 0.63, y = 76.4 + 1.8 x, p <0.001)
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Figures 18a-d:The temporal relationship between serum IL-6 and CRP 
concentrations after surgery in 4 surgical categories.
(in each figure, the left-hand vertical axis represents median serum 
IL-6 concentration (units/ml) and the right-hand vertical axis 
represents median serum CRP concentration (mg/1))
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Figure 19 : The association between integrated IL-6 and CRP responses in 28 
surgical patients.
(r = 0.63, y = 143.0 + 0.3 x, p <0.001).
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Temperature charts were available from 19 of these 28 patients. Axillary 
temperature rose in all 19 patients and peaked approximately 12 hours post­
incision. Figures 20a-d illustrate the time course of the changes in axillary 
temperature relative to serum IL-6 in four of the six surgical groups (for ease of 
presentation the minor group is not shown). In each group, changes in IL-6 
concentration parallel those in temperature, and the peak serum IL-6 and the peak 
temperature occur within a few hours of each other. Moreover a significant 
association exists between peak serum IL-6 and peak axillary temperature in these 
19 patients (figure 21) (r = 0.53, y = 37.0 + O.OOlx, t = 2.59, p = 0.019).
The changes in serum iron concentration and iron/transferrin ratio are shown in 
figures 22a and b, and can be seen to mirror one another. Iron concentration and 
iron/transferrin ratio fell between 0 and 12 hours post-incision in all 22 patients 
except the major vascular patient (who exhibited no change in iron levels). By 48 
hours, iron and iron/transferrin ratio had fallen substantially in the major vascular 
patient, and remained low in all the other patients. Indeed, the hip group and the 
vascular group exhibited further falls in iron and iron/transferrin ratio between 12 
and 48 hours post-incision. The extent of the reductions in iron and iron/transferrin 
ratio appears not to depend on the severity of the surgical procedure performed - an 
observation confirmed in figure 23, which shows considerable overlap in reduction 
in iron/transferrin ratio among the groups. Figure 24 illustrates the poor association 
between serum IL-6 response area and reduction in iron/transferrin ratio over the 
first 12 hours post-incision (r = -0.33, y = 4.9 - 0.003x, t = -1.59, p = 0.128).
Serum zinc and zinc/albumin ratio had fallen in all 25 patients by 12 hours post­
incision in all groups (figure 25a and b). By 48 hours zinc levels were returning to 
normal in all groups other than the hip group. Unlike iron/transferrin ratio, 
reductions in the zinc/albumin ratio tended to be smaller in the groups undergoing 
more minor surgery (table 12, figure 26). Figure 27 illustrates the significant
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Figures 20a-d : The temporal relationship between serum IL-6 concentration and 
axillary temperature in four surgical categories.
(in each figure the left-hand vertical axis represents median serum IL-6 
concentration (units/ml) and the right-hand vertical axis represents median axillary 
temperature (°C)).
Pe
ak
 
ax
ill
ar
y 
te
m
pe
ra
tu
re
 
(°
C
)
106
3 8 . 0 i
37 .5 -
37 .0 -
36 .5 -
36.0
0 200 4 0 0 6 0 0 8 0 0
Peak serum IL-6 concentration (units/ml)
Figure 21 : The association between peak serum IL-6 concentration and peak 
axillary temperature in 19 surgical patients.
(r = 0.53, y = 37.0 + 0.001 x, p = 0.019)
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Figures 22a,b : The changes in (a) serum iron concentration and
(b) iron/transferrin ratio following surgery in 6 surgical categories.
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Figure 23 : Comparison of the magnitude of the reductions in iron/transferrin ratio 
in the first 12 hours post-operation among 5 surgical categories.
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Figure 24 : The association between integrated IL-6 response and reduction in 
iron/transferrin ratio in the first 12 hours post-surgery in 22 surgical 
patients.
(r = -0.33, y = 4.9 - 0.003 x, p = 0.128)
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Figures 25a,b : The changes in (a) serum zinc concentration and (b) zinc/albumin 
ratio following surgery in 6 surgical categories.
I l l
Surgical Category Reduction in zinc/albumin ratio in first 
12 hours post-operation (pmol/g)
Minor (n = 6) 0.03 (0.0 - 0.1)a
Moderate (n = 3) 0.03 (0.02 - 0.05)b
Hip (n = 6) 0.08 (0.03-0.18)
Vascular (n = 4) 0.18(0.11 -0.24)c
Colorectal (n = 5) 0.12 (0.09 - 0.20)d
Major Vascular (n = 1) 0.19
a<c, W = 21.0, p = 0.014, 95% Cl = (-0.22, -0.07) 
a<d, W = 22.5, p = 0.017, 95% Cl = (-0.17, -0.03) 
b<d, W = 6.0, p = 0.037, 95% Cl = (-0.18, -0.04)
(all differences tested using Mann Whitney test)
Table 12: Reduction in zinc/albumin ratio in the first 12 hours post-operation in
6 surgical categories.
Results are expressed as median (range).
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Figure 26 : Comparison of the magnitude of the reduction in zinc/albumin ratio in 
the first 12 hours post-operation among 6 surgical categories.
(2 patients in the minor group showed no reduction in zinc/albumin 
ratio)
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Figure 27 : The association between integrated IL-6 response and reduction in 
zinc/albumin ratio in the first 12 hours post-surgery in 25 surgical 
patients.
(r = 0.56, y = 0.05 + 0.001 x, p = 0.003)
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correlation between integrated serum IL-6 response and reduction in zinc/albumin 
ratio (r = 0.56, y = 0.05 + O.OOlx, t = 3.26, p = 0.003).
In figures 28a and b, the timecourse of the IL-6 response in our 5 cholecystectomy 
patients is compared with that of the changes in iron/transferrin and zinc/albumin 
ratios in 9 cholecystectomy patients studied previously (140). Iron/transferrin ratio 
reaches its nadir approximately 12 hours post-incision (3 hours after peak IL-6 
levels) but the ratio remains low despite a fall in circulating IL-6 levels. Peak 
serum IL-6 concentrations occur at approximately the same time as the trough of 
zinc/albumin ratio (9 hours post-incision), and there is a strikingly close inverse 
relationship between these two variables.
SUMMARY
Serum IL-1 and TNFa levels remained undetectable in the 15 patients in whom 
they were measured. In contrast, serum IL-6 rose in all 28 patients and was 
strongly associated with duration of surgery. Serum CRP was less closely 
associated with duration of surgery. Serum IL-6 was significantly associated with 
serum CRP, with peak axillary temperature, and with reduction in zinc/albumin 
ratio. However, there was poor correlation between serum IL-6 and reduction in 
iron/transferrin ratio. Peak serum IL-6 levels occurred 20-40 hours before peak 
CRP levels, approximately 3 hours before peak temperature and at around the 
same time as lowest zinc/albumin ratio.
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Figures 28a,b : The temporal relationship between serum IL-6 concentration and (a) 
iron/transferrin ratio, (b) zinc/albumin ratio.
(The IL-6 data are from the 5 cholecystectomy patients studied here; the metal data 
are from 9 cholecystectomy patients studied previously)
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Clinical Value of IL-6
SURGICAL COMPLICATIONS
Ten of the 39 surgical patients studied developed complications post-operation 
(table 9). These 10 patients came from 4 of the 6 surgical categories and details 
of the complications are shown in table 13. Complications are divided into those 
which occurred within the first 4 post-operative days and those which developed on 
days 5 to 7.
The serum IL-6 responses in patients who developed complications are compared 
with the median response of those who did not in the same four surgical groups in 
figures 29a-d. The initial increase in all the patients with complications parallels 
that in the patients without complications. Patients without complications exhibit 
peak IL-6 levels at around 9 hours post-operation and 5 of the patients who 
developed complications had much higher IL-6 concentrations at 9 hours post­
operation. By 24 hours, 8 of the 10 patients who developed complications had IL-6 
levels which were higher than the median concentrations in the relevant groups. 
Interestingly, the 2 patients (patients 3 and 7, table 13) whose 24 hour IL-6 
concentrations were similar to those in the patients without complications were the 
2 patients in whom complications did not develop until the 6th and 7th day post­
operation. One of these patients exhibited an increase in IL-6 96 hours post­
operation (unfortunately, a 96 hour sample was not obtained from the other 
patient).
The corresponding data for CRP are presented in figures 30a-d. It is apparent that 
CRP discriminates less well between complicated and uncomplicated patients and 
that differences, if they occur at all, do so only 48 hours post-operation.
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Surgical
Category
Patient Nature of Complication Outcome at 
6 weeks
First 4 days 
post-surgery
Days 5 to 7 
post-surgery
Moderate 1 Unexplained pyrexia 
48 hours post-op.
Alive
2 Pyrexia 60 hours 
post-op.
Chest infection
Alive
Colorectal 3 Pyrexia day 7. 
DVT and PTE
Alive
4 Unexplained pyrexia 
12 hours post-op.
Alive
5 Dyspnoea 48 hours 
post-op but 
apyrexial.
Pleural effusion
Dead
6 Pyrexia 36 hours 
post-op.
Septic shock
Dead
7
Pyrexia and 
abdominal pain 
day 6.
Bowel infarction.
Alive
Vascular 8 Unexplained pyrexia 
48 hours post-op.
Alive
9 Wound infection 
48 hours post-op.
Alive
Major
vascular
10 Pyrexia and hypoxia 
24 hours post-op. 
Bronchopneumonia
Alive
Table 13: Clinical details of the 10 patients who developed complications post-
operation.
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Key: uncomp = patients without complications; comp pt = patient with
complications (table 13)
Figures 29a-d : Comparison of the serum IL-6 response in patients who developed 
complications with the median serum IL-6 response in 
uncomplicated patients from the same surgical category: 
a = moderate; b = vascular; c = colorectal; d = major vascular.
(the vertical axis represents serum IL-6 concentration (units/ml))
(Serum IL-6 levels in complicated patient 6 rose to >5000 units/ml 
and remained very high)
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Figures 30a-d: Comparison of the serum CRP response in patients who developed 
complications with the median serum CRP response in 
uncomplicated patients from the same surgical category: 
a = moderate; b = vascular; c = colorectal; d = major vascular
(the vertical axis represents serum CRP concentration (mg/1))
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Table 14 compares the 24 hour IL-6 and CRP results in patients having early 
complications (i.e. within 4 days) with those in the patients without complications, 
along with details of the length of operation and length of hospital stay post­
operation. There was no difference in the lengths of operation between patients 
with and without complications. Post-operative stay in the 8 patients with 
complications (median (range): 14 (5-26) days) was longer overall (Mann
Whitney test, W = 196.0, p = 0.001, 95% Cl = (2,14)) than in the 16 patients who 
made uncomplicated recoveries (8.5 (4-12) days). There was no difference in 24 
hour CRP levels between patients with and without complications. However, all 
patients with early complications had 24 hour IL-6 concentrations which were 
higher than those of any of the patients undergoing similar surgery (i.e. those in the 
same surgical group) who did not develop complications. 24 hour IL-6 levels 
overall in the 8 patients who developed early complications (median (range): 543 
(108->5000) units/ml) were significantly higher (Mann Whitney test, W = 141.0, p 
= 0.013, 95% Cl = (52, 925)) than those overall in the 16 patients without 
complications in the same four surgical groups (181 (22-529) units/ml).
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Surgical
Group
Duration of 
surgery 
(minutes)
Serum IL-6 
24 hours 
post-op. 
(units/ml)
Serum CRP 
24 hours 
post-op. 
(mg/1)
Duration of 
hospital stay 
post-op 
(days)
Outcome at 6 
weeks post­
op.
Moderate
Uncomp 
(n = 5)
75(45-135) 56(22-84) 111(41-133) 5(4-5) All alive
Comp Pt 1 45 183 100 5 Alive
Comp Pt 2 55 108 131 7 Alive
Colorectal
Uncomp 
(n = 6)
110(75-270) 207(141-397) 163(103-259) 8.5(7-12) All alive
Comp Pt 4 140 619 223 24 Alive
Comp Pt 5 125 947 85 26* Dead
Comp Pt 6 120 >5000 180 17* Dead
Vascular
Uncomp 
(n = 4)
85(75-160) 200(148-244) 126(60-175) 10 All alive
Comp Pt 8 85 467 150 10 Alive
Comp Pt 9 135 256 86 12 Alive
Major
Vascular
Uncomp 
(n = 1)
225 529 160 11 Alive
Comp Pt 10 240 1434 145 16 Alive
Key: Uncomp = patients without complications (results expressed as median
(range)).
Comp Pt = patient with complications
^indicates patient died on that day
Table 14: Comparison of duration of surgery, serum IL-6 and CRP concentrations 
24 hours post-operation, and duration of post-operative hospital stay 
between patients who had uncomplicated post-operative courses and 
those in the same surgical category who developed complications within 
the first 4 days post-surgery. (Patients 3 and 7 have been excluded since 
clinical complications did not occur until after the fourth post-op day).
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SUSPECTED MYOCARDIAL INFARCTION
Clinical details for the 15 patients presenting with chest pain are shown in table 15. 
Five patients were diagnosed as having unstable angina, and ten as having 
myocardial infarction. The time interval from onset of symptoms to admission to 
hospital did not differ significandy between the unstable angina pectoris group and 
the myocardial infarction group. Three of the patients who had sustained 
infarctions were dead at 6 weeks post-infarction.
The scatter of admission IL-6 concentrations in the 2 groups is shown in figure 31. 
Admission IL-6 concentrations were higher (Mann Whitney test, W = 105.0, p = 
0.003, 95% Cl = (19, 227)) in the infarct patients (median (range) 120 (77-295) 
units/ml)) than in the angina group (62 (29-72) units/ml). More important 
clinically, admission IL-6 discriminated completely between those patients with 
angina pectoris and those who had an acute infarct. In other words, using 75 
units/ml as a cut-off, the sensitivity and specificity were 100% albeit on small 
numbers. Admission CRP concentrations did not differ between the 2 groups 
(figure 32). Although all patients with angina had undetectable CRP levels, 6 
patients with infarcts also had undetectable levels. Some infarct patients had very 
high CK levels on admission, but overall these levels did not differ significantly 
between myocardial infarction patients and angina patients (figure 33).
Consequently, admission IL-6 was the best discriminant between those who had 
and those who had not sustained myocardial infarctions.
Figures 34a-c show the association between LVEF on the third hospital day and 
admission serum IL-6, CRP and CK concentrations respectively. A good negative 
correlation exists (r = -0.87, y = 364 - 5.2x, t = -6.38, p <0.001, 95% Cl = (3.5, 
7.0)) between admission IL-6 and LVEF at 3 days. The correlation for admission 
CRP is poorer (r = -0.60, y = 56 - 0.9x, t = -2.68, p = 0.019,95% Cl = (-1.6, -0.2))
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Patient Diagnosis Delay between onset of 
symptoms and 
admission (hours)
Outcome at 
6 weeks
1 Angina 8 Alive
2 Angina 2 Alive
3 Angina 6 Alive
4 Angina 4 Alive
5 Angina 12 Alive
6 MI 8 Alive
7 MI 12 Dead
8 MI 16 Alive
9 MI 2 Alive
10 MI 4 Alive
11 MI 9 Alive
12 MI 21 Alive
13 MI 18 Alive
14 MI 11 Dead
15 MI 24 Dead
Key: MI = myocardial infarction
Table 15: Clinical details in 15 patients presenting with suspected myocardial
infarction.
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Figure 31 : Comparison of serum IL-6 concentrations on admission between 
patients with angina and those with myocardial infarction.
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Figure 32 :Comparison of serum CRP concentration on admission between 
patients with angina and those with myocardial infarction.
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Figure 33 : Comparison of serum CK activity on admission between patients with 
angina and those with myocardial infarction.
(One myocardial infarction patient had a CK of 4200 IU/1 which has not been 
shown)
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LVEF (%)
The associations between LVEF on the third hospital day and:
(a) admission serum IL-6 concentration (r = -0.87, y = 364 - 5.2 x, 
p <0.001); (b) admission serum CRP concentration (r = -0.60, y = 
56 - 0.9 x, p = 0.019; (c) admission serum CK activity (r = -0.43, y 
= 2363 - 32.7 x, p = 0.112) in 15 patients with suspected 
myocardial infarction.
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and that for admission CK is poorer still (r = -0.43, y = 2363 - 32.7x, t = -1.70, p = 
0.112)), although peak CK levels had a correlation coefficient of -0.67 (data not 
shown). These results suggest that IL-6 concentration on admission may be a 
useful predictor of residual left ventricular function. Moreover, the 2 patients with 
the highest IL-6 levels on admission died although one of these patients also had 
the highest CK level (and an undetectable CRP), and the third patient who died did 
not have a particularly high admission IL-6. Nevertheless IL-6 was found to 
discriminate between myocardial infarction and angina, and to be closely associated 
with 3-day LVEF.
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ACUTE PANCREATITIS
Of the 23 patients with pancreatitis, 10 patients were classified retrospectively as 
having severe attacks and 13 as having mild attacks. The clinical details of these 
patients are presented in tables 16a and b.
There were no significant differences between the 2 groups in serum amylase 
concentration on admission, or in the time interval between the onset of symptoms 
and admission. Not surprisingly, patients with severe attacks had significantly 
longer (Mann Whitney Test, W = 176.0, p = 0.006, 95% Cl = (6,17)) hospital stays 
(median (range): 19 (7-27) days) than those with mild disease (8 (1-12) days). 
Patients with severe attacks had higher (Mann Whitney test, W = 163.5, p = 0.004, 
95% Cl = (0,3.0)) Glasgow scores (median (range): 2.5 (0-5)) than those with mild 
(0 (0-3)) (tables 16a and b) but 5 of the 10 severe patients had Glasgow scores less 
than 3. The diagnostic efficiency of this score was 74% (table 17).
The median serum IL-6 responses in the 2 groups are shown in figure 35. The 
pattern of the IL-6 response post-admission for each patient obviously depends on 
the time between onset of symptoms and admission. However, since there was no 
overall difference in this time between the 2 groups, then it is valid to compare the 
2 responses. Peak IL-6 levels occurred approximately 24 hours post-admission in 
the severe group, and within 20 hours of admission in the mild group. Admission 
EL-6 concentrations and peak IL-6 concentrations appear higher in severe 
pancreatitis patients and are shown in more detail in figures 36 and 37. (The 
highest IL-6 concentration in the severe group (1216 units/ml) has been omitted 
from figure 36). Admission and peak IL-6 concentrations were significantly 
higher (Mann Whitney test W = 176.0, p <0.001 for both, 95% Cl = (56, 199) and 
(142, 458) respectively) in the severe group (median (range): 135 (67-1216)
units/ml and 370 (163-1408) units/ml respectively) than in the mild group (36 
(<14 - 177) units/ml and 84 (25-237) units/ml respectively).
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Patient Delay between onset 
of symptoms and 
admission (hours)
Admission
Amylaseam
Glasgow
Score
Hospital stay 
(days)
Complication
1 12 851 0 12 None
2 6 1076 0 8 None
3 58 730 0 6 None
4 4 2298 0 8 None
5 34 1436 1 7 None
6 13 5660 0 5 None
7 12 5040 0 10 None
8 20 2700 3 1 None
9 6 841 0 5 None
10 6 5250 0 12 None
11 8 1283 1 12 None
12 1 4520 0 8 None
13 9 1263 0 6 None
Table 16a: Clinical details of 13 patients with mild acute pancreatitis.
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Patient Delay between onset 
of symptoms and 
admission (hours)
Admission
Amylase
(IU/1)
Glasgow
Score
Hospital Stay 
(days)
Complications
14 15 1975 5 25
Respiratory
failure
15 22 3890 0 14 Pancreatic
pseudocyst
16 7 4720 2 12 Pancreatic
collection
17 72 1276 3 18 Pancreatic
collection
18 15 3110 5 27 Slow recovery
19 72 3240 3 24 Slow recovery
20 24 2199 3 24 Slow recovery
21 12 3870 2 20 Pancreatic 
pseudocyst 
Respiratory and 
renal failure
22 10 1608 1 15 Pancreatic
pseudocyst
23 12 1740 0 7 Pancreatic
pseudocyst
Table 16b: Clinical details of 10 patients with severe acute pancreatitis.
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TEST
Admission Serum 
IL-6 
Concentration 
>70 units/ml
Peak Serum 
IL-6 
Concentration 
> 200 units/ml
Peak Serum CRP 
Concentration 
> 150 mg/1
Glasgow Score 
>3
Sensitivity 90% 90% 90% 50%
Specificity 85% 77% 85% 92%
PPV 82% 75% 82% 83%
NPV 92% 91% 92% 71%
Efficiency 87% 83% 87% 74%
Key: PPV = positive predictive value; NPV = negative predictive value.
Table 17: Performance characteristics of 4 indicators of severe acute pancreatitis.
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Figure 35 : Serum IL-6 response following admission in patients with mild and 
patients with severe pancreatitis.
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Figure 36 :Comparison of serum IL-6 concentration on admission between 
patients with mild and patients with severe pancreatitis.
(one patient with severe pancreatitis had a serum IL-6 concentration 
on admission of 1216 units/ml which has not been shown)
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Figure 37 : Comparison of peak serum IL-6 concentration between patients with 
mild and patients with severe pancreatitis.
136
More relevant clinically is the diagnostic reliability of serum IL-6 as a predictor of 
severe pancreatitis. The performance characteristics of admission serum IL-6 
concentration and peak IL-6 concentration as tests to diagnose a severe attack of 
pancreatitis are shown in tablel7. The cutoff point used for admission IL-6 
concentration is 70 units/ml and that for peak IL-6 concentration is 200 units/ml. 
The overall diagnostic efficiency of admission IL-6 is slightly better than that of 
peak IL-6. It also has the advantage of being available some 20 hours before peak 
IL-6 levels occur. Thus serum IL-6 concentrations around the time of admission 
may prove useful in selecting patients liable to develop complications once the 
diagnosis of acute pancreatitis has been made.
Peak CRP levels occur approximately 30 hours post-admission in the mild group 
and later, at approximately 40 hours post-admission, in the severe group (figure 
38). In both groups, the peak IL-6 has preceded the peak CRP by 15-20 hours. 
Differences in serum CRP concentration between the groups do not become 
apparent until approximately 24 hours post-admission. By the time peak levels 
have been reached, this difference has become marked. Figures 39 and 40 show 
admission and peak CRP values in the 2 groups and confirm the lack of 
discrimination between the groups using admission CRP. However, peak CRP 
levels are significantly higher (Mann Whitney test, W = 180.0, p <0.001, 95% 
Cl = (87, 230)) in the severe pancreatitis patients (median (range): 239 (100-429) 
mg/1) than in the mild pancreatitis patients (68(16-175) mg/1). Using a cut-off of 
150 mg/1, the diagnostic efficiency of this test was 87% (table 17). However, the 
major disadvantage of this test is that it can only be applied at least 24 hours after 
admission.
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Figure 38 : Serum CRP response following admission in patients with mild and 
patients with severe pancreatitis.
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Figure 39 : Comparison of serum CRP concentration on admission between 
patients with mild and patients with severe pancreatitis.
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Figure 40 : Comparison of peak serum CRP concentration between patients with 
mild and patients with severe pancreatitis.
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RHEUMATOID ARTHRITIS
Serum IL-6 concentrations were raised in 27 of the 33 patients with rheumatoid 
arthritis (figure 41). There was a weak but significant correlation between the 
Ritchie Articular Index and serum IL-6 concentration (r = 0.35, y = 27.6 + 3.4 x, 
t = 2.10, p = 0.044, 95% Cl = (0.1, 6.7)) (figure 42a). There was no association 
between Ritchie Articular Index and either CRP or ESR (figures 42b and c). 
Consequently, serum IL-6 appears to reflect disease activity more accurately than 
serum CRP or ESR.
Interestingly, the correlation between IL-6 and CRP in these patients with 
chronic disease (r = 0.65, y = 19.3 + 0.3x, t = 4.55, p <0.001, 95% Cl = (0.2, 0.4)) 
(figure 43) was similar to that found in the 28 surgical patients.
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Figure 41 : Comparison of serum IL-6 concentration between healthy volunteers 
(normal) and patients with rheumatoid arthritis (RA).
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Figures 42a-c : The associations between RitchieArticular Index and:
(a) serum IL-6 concentration (r = 0.35, y = 27.6 + 3.4 x, p = 
0.044); (b) serum CRP concentration ( r = 0.06, y = 37.0 + 0.25 x, 
p = 0.753); (c) ESR (r = 0.15, y = 69.6 - 0.83 x, p = 0.411) in 33 
patients with rheumatoid arthritis.
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Figure 43 : The association between serum IL-6 and CRP concentrations in 33
patients with rheumatoid arthritis.
(r = 0.65, y = 19.3 + 0.3 x, p <0.001)
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SUMMARY
Serum IL-6 levels were higher 24 hours post-operation in surgical patients who 
went on to develop clinical complications than in those who did not. There was no 
difference in CRP levels at this time. Serum IL-6 concentrations discriminated 
well on admission between patients with angina and those with myocardial 
infarction, and between patients with mild and those with severe attacks of 
pancreatitis. Serum CRP on admission was of no value in these situations. 
Moreover, there was good correlation between admission IL-6 levels and LVEF 
on the third hospital day in patients with chest pain. There was poor though 
significant correlation between serum IL-6 and the Ritchie Articular Index in 
patients with rheumatoid arthritis, while no association was found between the 
Ritchie Articular Index and CRP or ESR.
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DISCUSSION
IL-6 and the Acute Phase Response 
IL-1 AND TNFa
Baigrie et al recently reported measurable serum concentrations of IL-1 but not 
TNFa in the first few hours following surgery in all of six patients studied who 
underwent elective aortic surgery (170). In spite of intensive sampling during the 
first few hours we failed to detect either IL-16 or TNFa in any sample from the 15 
patients studied, some of whom underwent major hip and colorectal surgery. The 
concentrations of IL-1 reported by Baigrie et al are very low, the maximum being 
approximately 30 pg/ml. It is likely that this discrepancy is due to differing 
sensitivities of the immunoassays used. The Cistron assay quoted a detection limit 
of 20 pg/ml whereas the Medgenix assay used by Baigrie et al quoted a detection 
limit of 4 pg/ml. Consequently, any increases in serum DL-1B which occurred in 
our patients may have been too small for the Cistron immunoassay to detect. It is 
probable that surgery does provoke the release of large amounts of IL-1 locally, 
which may cause a small, short-lived increase in serum levels. In contrast, no 
increases in TNFa concentrations in serum were detected following surgery by 
either ourselves or Baigrie et al. The undetectable serum concentrations of IL-1B 
and TNFa found in our patients make it impossible to establish any quantitative 
relationship between these cytokines and CRP response, changes in plasma metal 
concentration, or changes in body temperature. Our findings, and those of Baigrie 
et al are compatible with the hypothesis that neither of these cytokines act 
systemically themselves to produce the principal manifestations of the acute phase 
response, and that they play a more local role which includes stimulation of IL-6 
production and release.
146
IL-6 RESPONSE TO SURGERY
The findings described here of increased serum concentrations of IL-6 in all 
patients post surgical incision make it likely that IL-6 does have an early and 
important role to play in the systemic inflammatory response. Detectable increases 
in serum IL-6 in all patients occurred within 2 to 4 hours of incision, in keeping 
with previous observations that in stimulated monocytes, IL-6 messenger RNA is 
detectable one hour post-stimulation becoming maximal after three hours (28). The 
timecourse of the IL-6 response following surgery recently reported by other 
workers parallels the time course seen in our patients (169,170,187). In general, 
the extent of the IL-6 response was related to the magnitude of tissue damage as 
reflected by the type of surgical procedure and the duration of the operation.
The possibility that duration of anaesthesia might have contributed to the response 
of IL-6 was investigated by studying the serum levels of IL-6 in the medical student 
(see Results Chapter, page 90) who underwent a particularly painstaking partial 
thyroidectomy. The peak IL-6 concentration was only 56 units/ml in spite of an 
operation which lasted 170 minutes, suggesting that duration of anaesthesia is not 
an important contributory factor.
Peak IL-6 levels were found to be representative of the integrated IL-6 response 
during the 48 hours post-incision. This implies that the serum EL-6 concentration 6 
to 12 hours after an acute event should reflect the overall IL-6 response and so the 
magnitude of underlying tissue damage. It should be noted however, that the 
nature of the response may partly depend on the site of injury since extra­
abdominal surgery (hip replacement) tended to produce a flatter, more drawn out 
IL-6 response than intra-abdominal surgery which involves bowel handling and 
which may be a potent stimulus to IL-6 production. The mechanism for this is 
unclear but our failure to detect endotoxin in sera of patients (unpublished data) 
suggests that it is not related to endotoxin release during bowel handling. These
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results overall are promising, however, and indicate that IL-6 may be useful as an 
early, sensitive, quantitative marker of tissue damage.
IL-6 AND C-REACTIVE PROTEIN
The hepatocyte stimulating effect of IL-6 is thought to be mediated mainly at the 
level of transcription (117), and maximal CRP synthesis in vitro has been shown to 
occur 20-30 hours after hepatocytes have been stimulated with IL-6 (238). The 
relative time courses of in vivo IL-6 and CRP responses observed in the present 
study are in keeping with these in vitro findings, and are consistent with IL-6’s 
being a major inducer of CRP synthesis. However, had this been the case, a 
stronger correlation between integrated IL-6 response and CRP response might 
have been expected, although, of course, this would not be proof of a causal role for 
IL-6 in CRP synthesis. To demonstrate conclusively that IL-6 induces either CRP 
synthesis or hypozincaemia, hypoferraemia or fever, one must show not only a 
good correlation between IL-6 levels and those other variables but also that 
injection of IL-6 into humans produces these effects at IL-6 concentrations 
comparable to those found here. To date, this has not been possible. Since a rather 
weak correlation between IL-6 and CRP was found, it may be postulated that IL-6 
is only one of several inducers of hepatic acute phase protein synthesis which may 
interact synergistically. Support for this view is lent by the findings of Morrone et 
al (117) who found that in Hep 3B cells, recombinant IL-6 only partially activated 
the CRP gene relative to the degree of activation produced by activated monocyte 
supernatant. This suggested that factors other than IL-6 are present in monocyte 
supernatant which are required either alone or in combination with IL-6 to 
stimulate maximal CRP synthesis. Moreover, Baumann et al (239) have 
demonstrated that optimal Hep G2 acute phase protein synthesis required 
stimulation by a combination of IL-6, IL-1 and dexamethasone. Thus it appears 
unlikely that IL-6 is the only inducer of CRP synthesis. Another explanation is 
that IL-6 does not act in a dose-dependent manner although in vitro work does not
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support this (116). Alternatively, the rather poor association between serum IL-6 
and CRP may reflect a poor relationship between serum IL-6 concentration and the 
local concentration at the physiologically active site.
IL-6 AND BODY TEMPERATURE
The relationship between IL-6 and body temperature is similar to that described for 
IL-6 and CRP although the time difference between changes in serum IL-6 
concentration and axillary temperature is much shorter. Nevertheless, again the 
temporal relationship supports IL-6’s putative role as an endogenous pyrogen, and 
is consistent with Le May et al’s report that following injection of dogs with LPS, 
peak plasma IL-6 concentration preceded peak rectal temperature by 2-3 hours 
(138), and again the correlation between peak IL-6 levels and peak body 
temperature is rather weak although highly significant. Considerations similar to 
those in the case of CRP apply - namely that IL-6 may not act in a dose-dependent 
manner or that systemic IL-6 levels may poorly reflect those which exert the 
pathophysiological effect at the hypothalamus. However, Le May et al (137) have 
reported that intraperitoneal injection of fever inducing doses of lipopolysaccharide 
in rats produced significant elevations of DL-6 concentrations in CSF and plasma, 
both of which showed good correlation with changes in body temperature (r = 0.77 
and r = 0.84 respectively) suggesting that IL-6 does behave in a dose-dependent 
manner and that physiologically relevant CSF levels do mirror systemic 
concentrations.
We have been unable to investigate whether the serum concentrations of IL-6 
observed in our patients are capable of inducing fever when produced 
experimentally, so we cannot state with certainty that IL-6 acts as endogenous 
pyrogen. Nevertheless, the most likely explanation for our findings is that IL-6 is 
indeed an endogenous pyrogen but does not act in isolation. Interestingly, Le May 
et al observed that very much higher doses of recombinant IL-6 administered 
intracerebroventricularly to rats and dogs were required to produce fever than were
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predicted by the CSF IL-6 concentrations which occurred following 
lipopolysaccharide administration (137,138). These findings support the 
hypothesis that the fever-inducing effect of IL-6 depends on or is magnified by the 
presence of other factors in the pathophysiological situation.
IL-6 AND HYPOFERRAEMIA AND HYPOZINCAEMIA
As we found no apparent relationship between reduction in iron/transferrin ratio 
and severity of surgical procedure, it is not surprising that there was no significant 
association between serum IL-6 response and reduction in serum iron/transferrin 
ratio, given that IL-6 has been shown to reflect the severity of surgical procedure. 
Moreover, the serum iron/transferrin ratio remained low although serum IL-6 levels 
were returning to normal. These findings make it unlikely that IL-6 plays an 
important role in inducing hypoferraemia and suggest that mechanisms distinct 
from those that induce acute phase protein synthesis are involved. Since IL-6 
appears to be a major inducer of acute phase protein synthesis, one might 
reasonably have expected the correlation between hypoferraemia and IL-6 to be 
similar to that for CRP and IL-6 (although to date there is no direct evidence that 
IL-6 stimulates ferritin synthesis). Consequently, hepatic ferritin synthesis may 
not be the major mechanism by which hypoferraemia is achieved. Alternatively, 
the lack of association may be because IL-6 is not involved in ferritin synthesis. 
IL-1 and TNFa have both been shown to produce hypoferraemia in vivo (127,154- 
156), and TNFa and IL-1 have been shown to stimulate ferritin heavy chain 
synthesis in murine and human muscle cell cultures (240,241) and human 
fibroblasts (242). It is possible, then, that IL-1 or TNFa may stimulate hepatic 
synthesis of ferritin directly but unlikely given that there are no reports of hepatic 
ferritin synthesis stimulated by IL-1 or TNFa and that IL-6 has been shown to be a 
much more potent stimulus to hepatocytes than either TNFa or IL-1 (112). The 
likeliest explanation for the lack of association is that mentioned above, namely
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that IL-6 is probably involved in ferritin synthesis but that this is not the major 
mechanism by which hypoferraemia is achieved.
Our findings, then, tend to support the lactoferrin hypothesis advocated by Van 
Snick (153) and backed by the findings of Goldblum et al who showed that 
endotoxin administration to rabbits and rats produced hypoferraemia which was 
neutrophil dependent and which could be reproduced by infusion of lactoferrin 
(154). However, it should be noted that Borish et al recently demonstrated in vitro 
that IL-6 could stimulate neutrophils to produce lactoferrin (243). Nevertheless the 
pathophysiological significance of this finding is unclear, and our results suggest 
that IL-6 is not a major factor in the production of the hypoferraemia of the acute 
phase response whatever the mechanism.
The significant correlation observed between serum IL-6 response and reduction in 
zinc/albumin ratio is compatible with a role for IL-6 in lowering plasma zinc 
concentrations by stimulating hepatic metallothionein synthesis. While a stronger 
correlation might be thought necessary to support (but not prove) a causal 
relationship between these variables, considerations similar to those in the case of 
CRP are applicable, namely that IL-6 probably does not act in isolation to induce 
metallothionein, or that serum IL-6 concentrations may not be an accurate 
reflection of tissue concentrations. Certainly the degree of association between IL- 
6 and reduction in zinc/albumin ratio is reasonably similar to that between IL-6 
and CRP responses, indicating that the mechanism which produces hypozincaemia 
(unlike that which produces hypoferraemia) may be similar to the mechanism 
producing hepatic synthesis of CRP albeit on a different timescale. Peak IL-6 
levels occurred approximately 9 hours post-incision in our 5 cholecystectomy 
patients, and lowest zinc/albumin ratios occurred at approximately the same 
time post-incision in the 9 cholecystectomy patients studied previously. The 
striking inverse relationship between changes in serum IL-6 and zinc/albumin ratio 
observed in these 2 groups of patients provides strong support for a role for EL-6 in
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the production of hypozincaemia. Moreover, the relative time courses of the IL-6 
and zinc responses are in keeping with the report that rat hepatocytes exhibit 
increased levels of metallothionein protein within 3 hours of stimulation with IL-6 
(163). Interestingly, too, the hip group in which IL-6 levels did not peak until after 
12 hours post-incision was the group in which zinc levels were still low at 48 hours 
post-incision.
Several in vivo studies have shown that IL-1 and TNF produce hypozincaemia 
when injected into animals (128,244,245). In particular, Cousins et al reported that 
administration of IL-1 to rats caused increased metallothionein gene expression 
resulting in a 14-fold increase in liver metallothionein and a transient depression of 
plasma zinc concomitant with zinc uptake by liver, thymus and bone marrow (246), 
while Karin et al found that IL-1 increased metallothionein gene expression in 
human hepatoma cells (247). However, Schroeder and Cousin reported that IL-6, 
but not IL-1, stimulated metallothionein in rat hepatocytes in the presence of 
glucocorticoids (163) although these findings have not as yet been repeated with 
human hepatocytes. Thus like other acute phase proteins (112), metallothionein 
gene expression appears to be dependent on IL-6 and glucocorticoids - results in 
keeping with previous observations that glucocorticoids stimulate metallothionein 
synthesis in vivo and in vitro (158,159). The reasons for the discrepancy between 
the in vitro results of Karin and those of Schroeder and Cousin are unclear but may 
involve differences in responsiveness among different cell lines. Nevertheless, it 
seems most probable that the in vivo actions of IL-1 reported by Cousins et al are 
mediated via IL-6. IL-1 and TNF cause release of IL-6 which in turn stimulates 
glucocorticoid secretion which in conjunction with IL-6 induces metallothionein 
expression causing hypozincaemia. Our findings are compatible with this 
hypothesis.
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Clinical Value of IL-6 
SURGICAL COMPLICATIONS
The 8 surgical patients who developed complications within 4 days of their 
operation had higher IL-6 levels 24 hours post-operation overall than those who 
did not develop complications. Furthermore, each of these 8 patients had higher 24 
hour IL-6 levels than any of the uncomplicated patients in the same surgical group 
although 6 of these 8 patients had no clinical evidence of complications at that 
time. These findings suggest that IL-6 has potential as a predictor of early 
complications. In contrast, at 24 hours post-surgery, CRP discriminated poorly 
between patients who went on to develop clinical complications and those who did 
not. The two patients who developed complications on the sixth and seventh post­
operative days had serum IL-6 concentrations 24 hours post-operation which were 
comparable to those in uncomplicated patients. This is not surprising since one 
would not expect a rise in serum IL-6 levels to precede the development of 
clinically apparent problems by more than 48 hours. Consequently, serum IL-6 on 
the first post-operative day would be of no value in selecting patients at risk of 
developing relatively late complications.
Given that the data from the uncomplicated surgical patients suggest that IL-6 is an 
early marker of tissue damage and that there are numerous reports of increased 
serum IL-6 levels in inflammatory, malignant and septic conditions, then the above 
results are to be expected. One would expect that any pathological process would 
result in continued or increased production of IL-6 since it appears to act as an 
inflammatory mediator. Very high levels of serum IL-6 have been reported in 
septic shock (168,180-182). In particular, a recent study of 40 critically ill 
surgical patients with documented sepsis found increased circulating levels of IL-6 
in all patients, and reported a significant correlation between serum IL-6 and 
APACHE II score - a scoring system which assesses severity of illness (r = 0.63, p
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<0.001). Moreover the mortality rate was higher (50% versus 21%) in patients 
whose IL-6 levels were greater than 1000 pg/ml suggesting that IL-6 may well have 
value as a predictor of mortality in septic patients (248). It is noteworthy that the 
patient in our group who developed septic shock and died (patient 6) had IL-6 
levels which were far in excess of those of any other patient. Moreover, the only 
other patient who died (patient 5) had the second highest IL-6 concentration 24 
hours post-operation.
The numbers here are small and consist of a heterogeneous group of patients. 
Nevertheless, there is a consistent pattern whereby serum IL-6 concentrations in 
patients who subsequently develop complications either fail to fall or increase post­
operation producing high serum levels which generally precede the onset of clinical 
signs by at least 12 hours. For example, both patients who died had relatively 
straightforward operations and were clinically stable 24 hours post-operation when 
IL-6 levels were very high. Clinical deterioration did not become obvious in either 
case until after 36 hours post-operation. This lead time could be of value in a 
clinical setting and allow selected patients to be monitored more intensively and/or 
treated earlier. All reports of elevated circulating IL-6 in patients with sepsis, 
some of which suggest that IL-6 may have value as a prognostic indicator, have 
studied patients in whom sepsis is established. To my knowledge, no other workers 
have reported elevated IL-6 levels prior to the development of clinical sepsis or 
other surgical complications. It should be possible to study larger numbers of 
patients and establish ranges of serum IL-6 concentrations which are ‘acceptable’ 
following different types of operation. Values in excess of this would prompt more 
detailed review of the patient. It should be noted that 3 patients with high IL-6 
levels 24 hours post-operation developed transient pyrexias of more than 38.5°C, 
which were unexplained and were associated with no adverse clinical 
consequences. It is possible then, that IL-6 might be too sensitive an indicator 
although this perhaps could be allowed for by setting cut-off points at an 
appropriate level. From our data, very high levels would suggest a serious
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problem such as developing septic shock. Although we have no direct evidence 
that earlier prediction of complications would improve patient outcome, it is not 
unreasonable to suggest that it should favourably influence patient management 
and perhaps facilitate the optimal use of limited resources.
SUSPECTED MYOCARDIAL INFARCTION
Admission IL-6 levels in patients with chest pain provided complete discrimination 
between those who had unstable angina and those who had myocardial infarction. 
The poor discrimination with CRP is not surprising given the lack of time between 
onset of symptoms and admission. This factor may also explain the finding of 
‘normal’ CK levels in 4 patients out of the 10 who had myocardial infarctions since 
CK levels do not peak until later than 24 hours post-infarction.
These results highlight the problems of using CK levels at presentation to diagnose 
myocardial infarction. A study of 639 patients presenting with acute chest pain 
found that the sensitivity of total CK on admission was only 38%, and that for 
CKMB on admission was even lower at 34% (although this rose to 57% if the 
sample was taken more than 12 hours after the onset of symptoms) (199). If serial 
measurements are used, the sensitivity is very good for total CK (98%) and near­
perfect for CKMB (100%) (249). The sensitivity of 60% for total CK on admission 
observed here is probably roughly comparable with the figure of 38% given that 
our numbers are very small and constitute a more highly selected population. In 
contrast IL-6 had a sensitivity of 100% in diagnosing infarction in our patients. 
Because of its non-specificity, IL-6 could be used as a marker of myocardial 
damage only if strong clinical evidence existed that a patient’s chest pain was 
cardiac in origin. If dubiety existed, then IL-6 would be less useful. In contrast, 
admission total CK activity and CKMB have been shown to be reasonably specific 
(80% and 88% respectively) (199).
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Early diagnosis of myocardial infarction has two major advantages:- it selects 
patients who might benefit from thrombolytic therapy; and it facilitates the rational 
use of coronary care unit beds which are a limited resource. The first of these in 
particular has produced a demand for emergency biochemical tests to help diagnose 
myocardial infarction. It is possible that in some patients, IL-6 might be helpful to 
diagnose myocardial infarction within the limitations mentioned above. However 
in practice, the diagnosis of myocardial infarction and the decision to administer 
thrombolytic therapy on clinical and ECG grounds is not usually difficult. In fact 
there is some evidence to suggest that those patients in whom ECG findings are 
equivocal do not experience as much benefit from thrombolytic therapy. The 
ISIS-2 study found that administration of streptokinase alone or in conjunction with 
aspirin produced substantial benefit in patients whose ECG showed anterior ST 
elevation but little benefit in those whose ECG showed ST depression or was 
‘normal’ (250). Thus it appears that the clinical value of admission IL-6 in the 
diagnosis of myocardial infarction may be limited, although it might be helpful in 
some difficult cases.
Depression of left ventricular function is known to be an important prognostic 
factor in coronary heart disease. Studies have demonstrated an association between 
LVEF measured with radionuclide angiography early after acute myocardial 
infarction and increased mortality during the subsequent year (251-253). In 1982, 
Sanz et al assessed 79 variables as predictors of late mortality in 259 men who 
survived acute myocardial infarction and were followed for a mean of 34 months. 
They found that LVEF (measured by left ventricular angiography) was the single 
best predictor of late survival (254). Mock et al studied more than 20,000 patients 
on the Coronary Artery Surgery Study Registry and found that LVEF (measured by 
radionuclide angiography) was a very important predictor of 4 year survival 
irrespective of the number of diseased coronary vessels (202). LVEF was 
measured in our patients by apical biplane cross-sectional echocardiography which 
has been found to produce similar results to both single-plane and biplane left
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ventricular radionuclide angiography (236). Consequently, the finding of a good, 
negative correlation between admission IL-6 and LVEF is of interest and suggests 
that IL-6 is potentially useful as a predictor of residual myocardial function and 
therefore of survival once the diagnosis of unstable angina pectoris or myocardial 
infarction had been made. Admission CRP proved to be less closely associated 
with LVEF, while the correlation between admission CK and LVEF was poorer 
still, although it was better for peak CK. Serial CKMB estimations can be used to 
estimate infarct size (r = 0.85-0.89) (256), but this involves frequent sampling and 
the use of complex mathematical models. Determination of peak CK and peak 
CKMB also involves serial measurements but the correlation reported between 
peak CK and infarct size (r = 0.68) (256) is not good and is similar to that found 
here for peak CK with LVEF. Given these relatively poor correlations, it is not 
surprising that peak CK levels are reported to be poor predictors of mortality post- 
myocardial infarction (200). Since IL-6 was closely associated with LVEF, one 
may speculate that IL-6 could prove useful as a prognostic indicator. Anecdotal 
support for this is provided by the observation that the two patients with the highest 
IL-6 levels both died. These results are promising but a much larger prospective 
study is required to confirm that IL-6 is helpful in diagnosing myocardial infarction 
in the acute situation, and that it has prognostic value in patients with acute 
episodes of myocardial ischaemia.
ACUTE PANCREATITIS
The relative temporal relationship between IL-6 and CRP response in the 
pancreatitis patients was reasonably similar to that found in the elective surgical 
patients, although actual peak IL-6 and CRP levels occurred later in the pancreatitis 
patients, particularly those with severe attacks. This finding is probably a reflection 
of differences in the types of insult - the controlled tissue damage of an elective 
surgical procedure versus the ongoing inflammatory process of an attack of acute 
pancreatitis. More importantly, our results suggest that serum IL-6 concentration at
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the time of admission discriminates well between severe and mild attacks of 
pancreatitis. Our finding that admission CRP levels did not discriminate confirms 
previous reports (206,257). These observations were to be expected given the time 
courses of IL-6 and CRP responses found following elective surgery. The delay 
between onset of symptoms and admission was variable in the pancreatitis patients 
but was usually less than 24 hours. Consequently, at admission one would have 
expected to find increased levels of IL-6 but not CRP.
The numbers involved in this study are small and larger numbers must be studied 
before definite conclusions can be drawn. However, admission IL-6, peak IL-6 and 
peak CRP concentrations all appear to have potential as severity indicators with 
roughly comparable efficiency, and were all more efficient at predicting severe 
attacks than the modified Glasgow score over which they have the added advantage 
of simplicity. The efficiency of peak CRP as a predictor of complicated attacks in 
this study is similar to that found by Wilson et al who studied 72 patients and 
found an efficiency of 85% using a cut-off concentration of 210 mg/1 (206). 
Moreover, a recent study of 50 patients reported after this work was performed 
concluded that serum IL-6 concentration at days 1 and 2 post-admission reflected 
the severity of acute pancreatitis (258). These workers quoted a positive predictive 
value of 91% and negative predictive value of 82% for serum IL-6 concentration in 
predicting a severe disease course - results roughly comparable with those found 
here for admission IL-6. It should be emphasised that both IL-6 and CRP are non­
specific and that levels may be used as severity indicators only once the diagnosis 
of pancreatitis has been made based on the clinical picture and serum amylase 
activity. (Our finding of no difference in admission serum amylase activity 
between the mild and severe groups confirms that serum amylase activity has no 
prognostic value).
The major advantage of admission IL-6 as a severity indicator is that it reduces the 
delay associated with using either CRP levels or complicated multifactorial scoring
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systems. Such delay is unacceptable since a severely ill patient can deteriorate 
appreciably within 24 to 48 hours. Furthermore, at this stage, clinical assessment is 
better at predicting the severity of an attack (figures quoted for percentage correct 
prediction are 73% (204) and 83% (205)), and so the relative value of biochemical 
tests becomes smaller. Thus, the earlier a test is available the more valuable it is 
for patient management. An IL-6 result within hours of admission could help to 
select patients at risk of complications who might require more intensive 
monitoring, and/or who might benefit from more invasive or more expensive 
diagnostic procedures such as peritoneal aspiration or CT scanning.
Peritoneal aspiration is capable of predicting the severity of an attack of acute 
pancreatitis at presentation, but it is an invasive technique involving a risk of 
visceral perforation which has not been widely adopted into clinical practice. 
Contrast enhanced CT scanning has been reported to distinguish mild from severe 
pancreatitis with sensitivity and specificity of 71% and 77% respectively (259). 
However, these values compare poorly with those for both IL-6 and CRP and, 
moreover, CT scanning is very expensive, is not universally available and involves 
transferring acutely ill patients from the therapy area.
Two other potential early severity indicators in acute pancreatitis have been 
reported recently, both of which seem promising. These are trypsinogen activation 
peptides (TAP) and polymorphonuclear (PMN) elastase.
Free trypsinogen activation peptides are produced during pathological 
intrapancreatic trypsinogen activation when they are released into the peritoneal 
cavity and circulation. These peptides are then rapidly cleared by the kidney and 
excreted in the urine. Severe necrotising pancreatitis is thought to differ from the 
milder oedematous form by the presence of intrapancreatic trypsinogen activation. 
Consequently, measurement of released trypsinogen activation peptides could have 
predictive value in acute pancreatitis. Gudgeon et al measured urinary TAP 
concentrations in 55 patients with acute pancreatitis at the time of admission (260).
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They found that this test predicted disease severity with a sensitivity of 80% and a 
specificity of 90% - diagnostic efficiency comparable with that which we have 
found for admission serum IL-6.
Polymorphonuclear leukocytes have a capacity to cause tissue damage which has 
been linked to the harmful potential of their lysosomal proteases, in particular 
elastase. The release of PMN elastase during the inflammatory response may be 
partly responsible for the tissue damage which occurs in many inflammatory 
pathologies, including acute pancreatitis, and this has prompted interest in the 
measurement of elastase as a severity indicator. A recent study of 182 patients with 
acute pancreatitis reported that admission serum elastase concentration predicted 
disease severity with a sensitivity of 93% and a specificity of 94% - diagnostic 
efficiency again comparable with admission IL-6 concentration (261).
Thus, although serum IL-6 on admission appears promising as a severity indicator 
once the diagnosis of acute pancreatitis has been made, two other promising 
indicators have been reported - PMN elastase and TAP. TAP may well have an 
advantage in that the other two are non-specific. Although the evidence to date 
suggests that the reliability of each test is comparable, the numbers studied are 
relatively small. Which of these is the single most reliable predictor of disease 
severity remains open to question, and a large prospective study in which all 3 of 
these parameters are measured and compared is necessary. The adoption of such 
tests into routine clinical practice is also likely to depend on available 
methodologies and sampling requirements. For example, the requirement of a 
urine sample for TAP assay may make this test less popular than one which 
requires serum or plasma.
160
RHEUMATOID ARTHRITIS
Other workers have reported elevated IL-6 in sera from patients with rheumatoid 
arthritis (219,223-224). Twenty-seven of our 33 patients had raised IL-6 
concentrations, the highest being 414 units/ml. Houssiau et al reported detectable 
(raised) serum IL-6 levels in only one third of 54 patients when measured using the 
7TDI bioassay (219). Moreover, all patients had concentrations less than 50 
units/ml. The discrepancy between these results and ours may be explained by the 
different definition of a ‘unit’. Houssiau et al define a unit as ‘the dilution giving 
half-maximal proliferation of cells’ which ‘corresponds to approximately 5 pg of 
IL-6’. In contrast, the unitage in this work corresponds to approximately one pg of 
IL-6. Hovdenes et al measured IL-6 levels in 24 patients with rheumatoid arthritis 
and found detectable levels in about half (223). However, direct comparisons with 
our results are difficult because of methodological differences (these workers used 
a different cell line in their bioassay). None of these workers related serum IL-6 
levels to clinical assessment of disease activity.
We found that serum IL-6 was weakly but significantly associated (r = 0.35) with 
clinical rheumatoid disease activity as assessed using the Ritchie Articular Index. 
In contrast, there was no correlation between either CRP or ESR and the Ritchie 
Articular Index. The presence of a significant correlation between serum IL-6 and 
Ritchie Articular Index is encouraging and not unexpected given that Miltenburg et 
al found a good correlation (r = 0.72, p <0.001) between the IL-6 concentration in 
synovial fluid and clinical assessment of local disease activity (222). Furthermore, 
Leisten et al reported good correlation (r = 0.88, p <0.01) between serum IL-6 
levels and the degree of inflammation quantitated by measuring paw volume in 
arthritic rats (262).
The radiograph has evolved into the ‘gold standard’ of the rheumatoid patient’s 
disease state because it is an objective method of assessing bone erosions (263).
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However, significant technical and interpretative problems continue to exist with 
radiographic assessment. More importantly, it is a measure which is not sensitive 
to change, and which involves a considerable lag time between the onset of the 
disease process and the presence of radiographic change (which may not be present 
until the cartilage is irreversibly destroyed) (264,265). Magnetic resonance 
imaging has been reported to detect early synovial proliferation but this technique 
remains prohibitively expensive (266). In the absence of a true ‘gold standard’, 
clinical scoring systems such as the Ritchie Articular Index have been used as 
objective measures of disease activity. Using this index we found that serum IL-6 
compared favourably with more conventional tests such as ESR and serum CRP as 
a marker of disease activity. These results are consistent with the findings from my 
study of surgical patients in which IL-6 was more closely associated with length of 
surgery than CRP. In the rheumatoid patients, however, there was poor correlation 
between IL-6 and no correlation between ESR and CRP and the Ritchie Articular 
Index. These results are surprising given the widespread measurement of ESR and 
CRP in patients with rheumatoid arthritis, although ESR is known to be affected by 
a variety of ‘non-inflammatory’ factors such as haematocrit. Other workers have 
reported conflicting results. Mallya et al found a significant correlation (r = 0.48) 
between serum CRP and the Ritchie Articular Index (226), whereas our findings are 
supported by Thompson et al who found no significant correlation between serum 
CRP and Ritchie Articular Index in 30 patients with rheumatoid arthritis (267). 
This lack of association may partly be due to the fact that the Ritchie Articular 
Index measures joint tenderness rather than overall inflammation (228). 
Nevertheless, joint tenderness is recognised as the most reliable measure of joint 
inflammation (268) and the discrepancy between our results and those of Mallya et 
al remains unexplained, although it is possible that inter-observer variation 
associated with scoring the Ritchie Articular Index is partly responsible. Certainly, 
in our patients it appears that IL-6 reflects the inflammatory process more 
accurately than does ESR or CRP.
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Two other analytes have been reported to be significantly associated with clinical 
measures of disease activity. Hyaluronic acid is a glycosaminoglycan that is a 
major component of connective tissue and is present in synovial fluid and synovial 
tissues. Concentrations increase in the serum of rheumatoid patients on mild 
exercise, and this increase has been found to show good correlation (r = 0.79, 
p <0.001) with the Ritchie Articular Index, suggesting that hyaluronic acid may 
prove useful as a disease marker (269) . It also has the advantage of being more 
specific than IL-6 or other acute phase reactants.
IL-1B concentrations in serum have also been found to have a weak but significant 
association with disease activity (r = 0.57, p <0.001) although considerable overlap 
existed between values for rheumatoid patients and normals (270).
The role of IL-6 in the pathogenesis of rheumatoid arthritis is not clear. IL-1 and 
TNFa cause arthritis in rabbits when injected intra-articularly (271). Both of these 
cytokines can stimulate prostaglandin E2 and collagenase production by synovial 
fibroblasts and chondrocytes (272-275) implicating them in the mechanism by 
which pannus formation causes cartilage and bone destruction. This is not the case 
for IL-6. It is possible that IL-6 is a product of, and does not contribute to, the 
inflammatory process within the joint, and orchestrates the ensuing systemic 
inflammatory and immune responses. Certainly, we and other workers (219) have 
found comparable correlations between serum IL-6 and CRP in rheumatoid 
patients (r = 0.65 and r = 0.69 respectively). These are similar to the correlation 
found in the surgical patients and suggest that IL-6 has the same role in CRP 
synthesis both acutely and in chronic conditions. Also, synovial derived IL-6 
stimulates immunoglobulin synthesis (49) and IL-6 levels have been found to show 
significant correlation with immunoglobulin concentrations in synovial fluid 
(221,276).
These results indicate that IL-6 compares favourably with CRP and ESR as a 
marker of disease activity in rheumatoid arthritis. However, both hyaluronic acid
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and, to a lesser extent, IL-16 look promising as such markers. Many more patients 
must be studied to determine which, if any, of these are reproducibly elevated in 
rheumatoid arthritis and which show good correlation with disease activity. 
Furthermore, longitudinal studies need to be performed to determine which of 
these parameters reflect changes in disease activity with the required sensitivity, 
and parallel the clinical course of the disease.
164
CONCLUSION
The findings from the study of 28 elective surgical patients provide support for the 
premise that IL-6 is a major mediator of such components of the acute phase 
response as hepatic CRP synthesis, increase in body temperature and 
hypozincaemia, but suggest that IL-6 is not involved in producing hypoferraemia.
The failure to detect TNFa or IL-16 in the sera of surgical patients indicates that 
neither of these cytokines is likely to act systemically to produce these 
manifestations of the acute phase response, and that they probably exert their 
effects locally.
Of more importance clinically is that these results indicate that IL-6 is a marker of 
tissue damage which has potential advantages over CRP. Serum levels increased 
much earlier than CRP and peak concentrations were more closely associated with 
degree of tissue damage as reflected by duration of surgery.
The finding of higher serum IL-6 levels 24 hours post-surgery in patients who went 
on to develop post-operative complications indicates its potential value in 
predicting those surgical patients at risk of developing complications. Admission 
levels of IL-6 discriminated completely between patients with unstable angina and 
those having had a myocardial infarction, whereas CRP and CK discriminated 
poorly. In addition, admission IL-6 was closely associated with LVEF on the third 
hospital day, suggesting that it may well have prognostic value. IL-6 on 
admission discriminated well between those patients who had mild attacks and 
those patients who had severe attacks of pancreatitis. In patients suffering from 
rheumatoid arthritis, serum IL-6 levels were more closely associated than either 
ESR or CRP with a clinical index of disease activity.
These results are promising and support the concept that IL-6 is a better 
quantitative marker of inflammation than CRP and may well prove to be a valuable
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marker of tissue damage in clinical practice. While IL-6 may be more useful than 
CRP (or ESR) in monitoring patients with chronic inflammatory conditions such as 
rheumatoid arthritis, it is likely to offer less benefit than in the acute situation. 
This is because the principal advantage of IL-6 over CRP in the acute situation is 
not that it provides a more accurate measure but that it provides an earlier measure 
of inflammation.
As is the case for CRP, one of the main limitations of IL-6 is likely to be its non­
specificity. Nevertheless, provided clinicians are aware of this, there is no 
theoretical reason why IL-6 should not fulfil a similar role to CRP, with the 
advantage that it has a 24-hour lead time. However, the numbers of patients 
studied here are small and many more patients must be studied to confirm the 
clinical value of IL-6 as a marker of tissue damage.
The premise that IL-6 has potential as a severity indicator in clinical practice is 
dependent on results being available within a few hours of sample collection. The 
major drawback of the IL-6 bioassay used here is the very long turnaround time of 
five days. However, several commercial manufacturers have recently developed 
immunoassay kits for EL-6 which are now being marketed (Quantikine Human IL- 
6, British Bio-technology Ltd., Abingdon, Oxon; Biokine IL-6 Test Kit, T Cell 
Sciences, Cambridge; COALIZA IL-6, Kabi Diagnostica, Sweden; IL-6 EASIA, 
IL-6 IRMA, Medgenix Ltd, High Wycombe, Bucks), and which are claimed to 
have turnaround times of less than 6 hours. Consequently, the methodology is now 
available to produce IL-6 results within the time scale necessary for these to be of 
value clinically, and comparisons between immunoassays and bioassays require to 
be performed. The immunoassay kits are expensive - approximately £10-00 per 
test. Nevertheless, it is important that such immunoassays are used in any future 
studies, such as those outlined in the preceding discussion, which aim to confirm 
the value of IL-6 in given clinical situations, since it is assays of this type which 
would be used should measurement of IL-6 be incorporated into routine practice.
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In conclusion, these results support the hypothesis that IL-6 is an important 
mediator of the systemic inflammatory response. The results reported in this thesis 
have shown that serum IL-6 is an early, quantitative, non-specific marker of tissue 
damage which offers potential advantages over CRP, particularly in acute clinical 
situations.
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